学术周报 · IF≥10

肾内科领域文献阅读汇编

2026年第41周 (2026-10-08) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
50
临床研究
40
基础研究
10
IF≥20
28
IF 10-20
22
子领域
9
期刊种类
27
数据日期
2026-10-08

★本周 Top 10 高影响力文献

#论文期刊IF
1Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.Nature medicineIF 52.5
2Transcription factor TBX2 is a key regulator of vascular calcification.European heart journalIF 45.3
3Serologic Immunity to Hepatitis A and B in US Adults and High-Risk Populations.JAMA internal medicineIF 26.3
4Development and validation of quality indicators for lupus nephritis, based on the 2025 EULAR recomm...Annals of the rheumatic diseasesIF 24.0
5How I treat thrombotic microangiopathy in the setting of triggers.BloodIF 23.9
6Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association (ADA) a...Diabetes careIF 22.6
7Fracture Risk Is Increased in Type 1 Diabetes and Is the Highest in Individuals With Diabetic Kidney...Diabetes careIF 22.6
8Ultra-early versus early adjunctive vasopressin initiation after norepinephrine escalation in septic...Intensive care medicineIF 22.0
9Antiseizure medication dosing and monitoring in the intensive care unit: a practical narrative revie...Intensive care medicineIF 22.0
10Comprehensive geriatric assessment for older people living with chronic kidney disease and frailty: ...Kidney internationalIF 21.8

Ŧ期刊分布统计

期刊篇数IF
Kidney international17IF 21.8
American journal of respiratory and critical care medicine2IF 21.7
Annals of internal medicine2IF 17.2
Diabetologia2IF 10.4
Diabetes care2IF 22.6
Redox biology2IF 16.2
Intensive care medicine2IF 22.0
Journal of the American Academy of Dermatology2IF 12.3
Ageing research reviews1IF 15.5
ACS sensors1IF 10.9

1慢性肾脏病 CKD (27篇)

临床研究 (23篇)

JAMA cardiology IF 15.2 2026-10-07 PMID: 42842238
There is uncertainty about the effects of intensive blood pressure (BP) lowering on risks of cardiovascular disease and kidney failure in patients with chronic kidney disease (CKD). To assess the standardized effects of intensive BP lowering on cardiovascular and kidney outcomes overall, and then to assess for effect modification by CKD status. MEDLINE and Embase databases were searched from inception to January 16, 2026. Randomized clinical trials comparing intensive vs standard BP lowering in adults with and without CKD, with at least 1 year of follow-up, were eligible for inclusion. Meta-analyses were performed using inverse variance weighting after standardizing trial results according to the between-group difference in achieved systolic BP (SBP). Differences in relative effects between CKD and non-CKD populations were assessed using χ2 tests for heterogeneity. The primary outcome was major cardiovascular events; secondary outcomes included kidney failure and estimated glomerular filtration rate (eGFR)-based surrogate outcomes for kidney failure. We identified 27 studies including 88 830 participants. Intensive BP lowering reduced the risk of cardiovascular events by 15% per 10-mm Hg lower SBP (relative risk [RR], 0.85; 95% CI, 0.81-0.89), without heterogeneity by CKD status. This corresponded to an estimated (SE) absolute reduction of 4.3 (1.2) cardiovascular events per 1000 person-years in individuals with CKD and 2.7 (0.4) events per 1000 person-years in those without CKD. Intensive BP lowering did not affect risk of kidney failure (RR per 10-mm Hg reduction, 0.97; 95% CI, 0.84-1.11) nor risk of 57% or 50% sustained eGFR declines (RR, 0.97; 95% CI, 0.83-1.14; and RR, 1.29; 95% CI, 0.94-1.76, respectively), without heterogeneity by CKD subgroup. Intensive BP lowering increased risk of 30% or greater and 40% or greater declines by 42% (RR, 1.42; 95% CI, 1.28-1.58) and 47% (RR, 1.47; 95% CI, 1.30-1.66). Results of this systematic review and meta-analysis indicate that in adults with or without CKD, intensive BP lowering reduced the risk of cardiovascular events by 15% per 10-mm Hg lower SBP and increased the risk of sustained declines in eGFR, without an increase in risk of kidney failure. However, since baseline cardiovascular risk is higher in CKD, the absolute reduction in cardiovascular events was at least as large in this population; therefore, intensive BP lowering should be recommended in people with and without CKD.
中文摘要:关于强化降压对慢性肾脏病(CKD)患者心血管疾病和肾衰竭风险的影响仍存在不确定性。本研究旨在总体评估强化降压对心血管和肾脏结局的标准化效应,并进一步评估CKD状态是否改变该效应。检索了MEDLINE和Embase数据库,自建库至2026年1月16日。纳入标准为在合并和不合并CKD的成人中比较强化降压与标准降压、随访至少1年的随机临床试验。在根据组间达到的收缩压(SBP)差异标准化试验结果后,采用逆方差加权进行荟萃分析。使用χ2异质性检验评估CKD与非CKD人群相对效应差异。主要结局为主要心血管事件;次要结局包括肾衰竭以及基于估算肾小球滤过率(eGFR)的肾衰竭替代结局。共识别27项研究,纳入88 830名参与者。强化降压使收缩压每降低10 mm Hg,心血管事件风险降低15%(相对风险[RR],0.85;95% CI,0.81-0.89),且按CKD状态无异质性。这相当于CKD患者每1000人年估计(标准误)绝对减少4.3(1.2)次心血管事件,非CKD者每1000人年减少2.7(0.4)次事件。强化降压未影响肾衰竭风险(收缩压每降低10 mm Hg的RR,0.97;95% CI,0.84-1.11),也未影响57%或50%持续eGFR下降的风险(RR,0.97;95% CI,0.83-1.14;以及RR,1.29;95% CI,0.94-1.76),且按CKD亚组无异质性。强化降压使30%或以上和40%或以上eGFR下降风险分别增加42%(RR,1.42;95% CI,1.28-1.58)和47%(RR,1.47;95% CI,1.30-1.66)。本系统综述和荟萃分析结果表明,在合并或不合并CKD的成人中,收缩压每降低10 mm Hg,强化降压可使心血管事件风险降低15%,并增加持续性eGFR下降风险,但未增加肾衰竭风险。然而,由于CKD患者的基线心血管风险更高,该人群中心血管事件的绝对减少至少同样大;因此,应在合并和不合并CKD的人群中推荐强化降压。
Annals of internal medicine IF 17.2 2026-10-06 PMID: 42832797
GIM/FP/GP: [Formula: see text] Nephrology: [Formula: see text].
中文摘要:普通内科/家庭医学/全科医学:[公式:见正文]。肾脏病学:[公式:见正文]。
Diabetologia IF 10.4 2026-10-02 PMID: 42825923
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the consensus statement on the management of type 2 diabetes in non-pregnant adults, published since 2006 and last updated In 2022. The target audience is the multidisciplinary healthcare team providing diabetes care in the USA and Europe. A systematic examination of publications since 2022 informed new recommendations. This update has broadened the focus from the management of hyperglycaemia to the holistic management of type 2 diabetes and its risk of associated multiple long-term conditions. Fundamental aspects of diabetes care include promoting healthy lifestyle behaviours (healthy eating, 24 h physical behaviours including sleep, and avoiding tobacco and substance use), alongside the provision of psychological support and weight management interventions. For the management of people living with type 2 diabetes, earlier use, potentially from diagnosis, of sodium-glucose cotransporter 2 (SGLT2) inhibitors or/and glucagon-like peptide-1 (GLP-1)-based therapies to offer organ protection and improve long-term outcomes in type 2 diabetes is advocated. Furthermore, earlier combination use of SGLT2 inhibitors and GLP-1-based therapies should be considered in people with concomitant CVD, chronic kidney disease and heart failure. Finally, the ability to transform outcomes for people living with type 2 diabetes is within our grasp through the consistent, equitable and systematic implementation of strategies and therapies that are already available.
中文摘要:美国糖尿病协会(ADA)与欧洲糖尿病研究协会(EASD)召集专家组,更新了自2006年发布、最近于2022年更新的非妊娠成人2型糖尿病管理共识声明。目标读者为在美国和欧洲提供糖尿病诊疗的多学科医疗团队。对2022年以来出版文献的系统性审查为新推荐提供了依据。本次更新将重点从高血糖管理扩展至2型糖尿病及其相关多种长期并发症风险的整体管理。糖尿病照护的基本方面包括促进健康生活方式行为(健康饮食、24小时身体行为包括睡眠,以及避免烟草和物质使用),同时提供心理支持和体重管理干预。对于2型糖尿病患者的管理,提倡更早使用,可能从诊断时开始,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂和/或基于胰高血糖素样肽1(GLP-1)的治疗,以提供器官保护并改善2型糖尿病的长期结局。此外,对于合并心血管疾病、慢性肾脏病和心力衰竭的患者,应考虑更早联合使用SGLT2抑制剂和基于GLP-1的治疗。最后,通过一致、公平和系统地实施已经可用的策略和疗法,我们有望改变2型糖尿病患者的结局。
Diabetes care IF 22.6 2026-10-02 PMID: 42825450
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the consensus statement on the management of type 2 diabetes in nonpregnant adults, published since 2006 and last updated in 2022. The target audience is the multidisciplinary health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2022 informed new recommendations. This update has broadened the focus from the management of hyperglycemia to the holistic management of type 2 diabetes and its risk of associated multiple long-term conditions. Fundamental aspects of diabetes care include promoting healthy lifestyle behaviors (healthy eating, 24-h physical behaviors including sleep, and avoiding tobacco and substance use), alongside the provision of psychological support and weight management interventions. For the management of people living with type 2 diabetes, earlier use, potentially from diagnosis, of sodium-glucose cotransporter 2 (SGLT2) inhibitors and/or glucagon-like peptide 1 (GLP-1)-based therapies to offer organ protection and improve long-term outcomes in type 2 diabetes is advocated. Furthermore, earlier combination use of SGLT2 inhibitors and GLP-1-based therapies should be considered in people with concomitant cardiovascular disease, chronic kidney disease, and heart failure. Finally, the ability to transform outcomes for people living with type 2 diabetes is within our grasp through the consistent, equitable, and systematic implementation of strategies and therapies that are already available.
中文摘要:美国糖尿病协会(ADA)与欧洲糖尿病研究协会(EASD)召集专家组,更新关于非妊娠成人2型糖尿病管理的共识声明,该声明自2006年发布,最近于2022年更新。目标读者是在美国和欧洲提供糖尿病诊疗的多学科医疗团队。对2022年以来发表文献的系统性审查为新的推荐意见提供了依据。本次更新将重点从高血糖管理扩展至2型糖尿病及其相关多种长期疾病风险的整体管理。糖尿病照护的基本方面包括促进健康生活方式行为(健康饮食、包括睡眠在内的24小时身体活动行为,以及避免烟草和物质使用),同时提供心理支持和体重管理干预。对于2型糖尿病患者的管理,提倡更早使用,可能从诊断时即开始使用钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂和/或胰高血糖素样肽1(GLP-1)为基础的治疗,以提供器官保护并改善2型糖尿病的长期结局。此外,对于合并心血管疾病、慢性肾脏病和心力衰竭的患者,应考虑更早联合使用SGLT2抑制剂与GLP-1为基础的治疗。最后,通过一致、公平且系统地实施已经可用的策略和疗法,我们有望改变2型糖尿病患者的结局。
Nature medicine IF 52.5 2026-10-01 PMID: 42823485
The GLP-1 receptor agonist semaglutide preserves kidney function in people with type 2 diabetes and chronic kidney disease, but the underlying mechanisms are unclear. Here we report a 52-week randomized trial of subcutaneous semaglutide 1 mg once weekly versus placebo (n = 106 (n = 25 women, n = 81 men)) in participants with type 2 diabetes and chronic kidney disease. To identify kidney-specific mechanisms of action for semaglutide, we performed integrated multiparametric magnetic resonance imaging of the kidney and biopsy for histology (n = 33), alongside single-nucleus (n = 22) and spatial transcriptomics (n = 13) on paired samples with before- and after-treatment measurements. Coprimary magnetic resonance imaging outcomes (oxygenation by R2*, global perfusion and tissue inflammation by T1 mapping) were not significantly altered by semaglutide versus placebo treatment. Secondary outcomes revealed that semaglutide treatment, as compared to placebo, was associated with a significantly reduced renal artery resistive index and stabilization of the apparent diffusion coefficient, indicating prevention of fibrosis progression. Moreover, secondary transcriptomic outcomes revealed pronounced effects of semaglutide on glomerular endothelial cells, consistent with the results of spatial analyses indicating reduced numbers of immune cells in the proximity of these endothelial cells. The results from this trial indicate that mechanisms of kidney protection by semaglutide may include reduced vascular resistance, prevention of fibrosis and improved underlying molecular programs promoting endothelial cell health. ClinicalTrials.gov identifier: NCT04865770 .
中文摘要:GLP-1受体激动剂司美格鲁肽可保护2型糖尿病合并慢性肾脏病患者的肾功能,但其潜在机制尚不清楚。在此,我们报告一项为期52周的随机试验,比较皮下注射司美格鲁肽1 mg每周一次与安慰剂(n=106(女性25例,男性81例))在2型糖尿病合并慢性肾脏病参与者中的效果。为识别司美格鲁肽的肾脏特异性作用机制,我们对肾脏进行了整合多参数磁共振成像,并进行活检用于组织学检查(n=33),同时对治疗前和治疗后配对的样本进行单核(n=22)和空间转录组学(n=13)分析。共同主要磁共振成像结局(通过R2*评估氧合、整体灌注以及通过T1 mapping评估组织炎症)在司美格鲁肽组与安慰剂组之间无显著改变。次要结局显示,与安慰剂相比,司美格鲁肽治疗与肾动脉阻力指数显著降低以及表观扩散系数稳定相关,提示可预防纤维化进展。此外,次要转录组学结局显示司美格鲁肽对肾小球内皮细胞有显著影响,这与空间分析结果一致,即这些内皮细胞附近的免疫细胞数量减少。该试验结果表明,司美格鲁肽肾脏保护机制可能包括降低血管阻力、预防纤维化以及改善促进内皮细胞健康的潜在分子程序。ClinicalTrials.gov注册号:NCT04865770。
European journal of heart failure IF 10.3 2026-10-01 PMID: 42817848
Heart failure (HF) remains a major cause of morbidity, mortality, and increased healthcare costs worldwide, and is recognized as the result of progressive cardiovascular-kidney-metabolic (CKM) syndrome. Obesity, type 2 diabetes, chronic kidney disease, hypertension, and atherosclerotic cardiovascular disease frequently coexist and interact through shared pathophysiological mechanisms that promote HF onset, especially with preserved ejection fraction (HFpEF). This European Journal of Heart Failure (EJHF) Expert Consensus Statement synthesizes contemporary evidence supporting pharmacological strategies to prevent HF across the CKM spectrum. Foundational therapies, including renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and incretin-based agents, demonstrate complementary benefits in reducing HF events, cardiovascular death, and chronic kidney disease (CKD) progression in high-risk populations. Early, parallel initiation of these therapies may modify disease trajectory and attenuate progression from at-risk and pre-HF stages to overt clinical HF. This document further emphasizes the need for an up-front, accelerated implementation strategy supported by structured monitoring, multidisciplinary CKM care pathways, and proactive management of laboratory abnormalities. Overcoming barriers such as clinical inertia, safety misperceptions, polypharmacy, cost constraints, and inequities in access is essential to translate evidence into population-level impact. Harmonization of prevention frameworks across cardiology, nephrology, endocrinology, and primary care societies is urgently required. Integrated, cross-disciplinary implementation of evidence-based CKM management offers a realistic opportunity to reduce incident HF and mitigate its growing global burden.
中文摘要:心力衰竭(HF)仍是全球发病、死亡和医疗费用增加的主要原因,并被认为是进行性心血管-肾脏-代谢(CKM)综合征的结果。肥胖、2型糖尿病、慢性肾脏病、高血压和动脉粥样硬化性心血管疾病常同时存在,并通过共同病理生理机制相互作用,促进HF发生,尤其是射血分数保留型(HFpEF)。本欧洲心力衰竭杂志(EJHF)专家共识声明综合了当代证据,支持在整个CKM谱系中预防HF的药物策略。基础治疗,包括肾素-血管紧张素系统抑制剂、钠-葡萄糖协同转运蛋白2抑制剂、非甾体类盐皮质激素受体拮抗剂和基于肠促胰素的药物,在高危人群中显示出减少HF事件、心血管死亡和慢性肾脏病(CKD)进展的互补获益。早期、并行启动这些治疗可能改变疾病轨迹,并减缓从高危和HF前期阶段向显性临床HF的进展。本文件进一步强调,需要采取前置、加速的实施策略,并以结构化监测、多学科CKM照护路径和实验室异常的主动管理为支持。克服临床惰性、安全认知误区、多重用药、费用限制和获取不平等障碍,对于将证据转化为人群层面影响至关重要。迫切需要在心脏病学、肾脏病学、内分泌学和初级保健学会之间协调预防框架。基于证据的CKM管理在跨学科整合实施,为减少新发HF并减轻其日益增长的全球负担提供了现实机会。
MedComm IF 14.1 2026-10 PMID: 42780637
Cardiovascular-kidney-metabolic (CKM) multimorbidity is common among patients with heart failure (HF), but its prognostic impact in Chinese patients remains largely unclear. We examined the relationship of CKM multimorbidity with adverse outcomes and its interaction with guideline-directed medical therapy (GDMT) in patients with HF. We classified hospitalized patients with HF by CKM-condition count (atherosclerotic cardiovascular disease [ASCVD], chronic kidney disease [CKD], and type 2 diabetes [T2D]). Cox models assessed 1-year all-cause death, cardiovascular (CV) death, and rehospitalizations. Among patients with HF with reduced ejection fraction (HFrEF), subgroup analyses were conducted by GDMT use. Among 126,524 patients, 66.4% had at least one CKM condition and 5.1% had all three. All-cause death increased with CKM burden; three conditions conferred the highest risk (adjusted hazard ratio 2.43, 95% confidence interval [CI] 2.20-2.69) versus no CKM conditions. Associations were stronger in HFrEF. Although GDMT recipients had lower absolute death rates, associations of CKM multimorbidity with all outcomes were generally consistent regardless of GDMT use. CKM multimorbidity is common in Chinese patients hospitalized with HF and is associated with a worse prognosis. Although GDMT lowered absolute death rates, it did not substantially modify the relative associations between CKM multimorbidity and subsequent clinical outcomes.
中文摘要:心血管-肾脏-代谢(CKM)多病共存常见于心衰(HF)患者,但其在中国患者中的预后影响仍大多不清楚。我们分析了心衰患者中CKM多病共存与不良结局的关系及其与指南导向药物治疗(GDMT)的交互作用。我们根据CKM疾病计数(动脉粥样硬化性心血管疾病[ASCVD]、慢性肾脏病[CKD]和2型糖尿病[T2D])对住院心衰患者进行分类。Cox模型评估了1年全因死亡、心血管(CV)死亡和再住院。在射血分数降低的心衰(HFrEF)患者中,按GDMT使用情况进行亚组分析。在126,524例患者中,66.4%至少有1种CKM疾病,5.1%有三种。全因死亡随CKM负担增加而升高;与无CKM疾病相比,三种疾病带来最高风险(校正风险比2.43,95%置信区间[CI]2.20-2.69)。这种关联在HFrEF中更强。尽管接受GDMT者的绝对死亡率较低,但无论是否使用GDMT,CKM多病共存与所有结局的关联总体一致。CKM多病共存在中国住院心衰患者中常见,并与更差预后相关。尽管GDMT降低了绝对死亡率,但并未实质性改变CKM多病共存与后续临床结局之间的相对关联。
Kidney international IF 21.8 2026-10 PMID: 42760022
Comprehensive geriatric assessment is an established intervention for older people living with frailty, involving multidimensional assessment and development of a personalized care plan to meet identified needs. The GOAL trial demonstrated that comprehensive geriatric assessment delivered through a single outpatient geriatrician appointment did not improve goal attainment for older people living with chronic kidney disease and frailty. Alternative models of comprehensive geriatric assessment and person-centered care require evaluation. Regardless, embracing person-centered care should be a goal set by all nephrology services.
中文摘要:综合老年评估是针对衰弱老年人已确立的干预措施,包括多维评估并制定个体化照护计划以满足已识别的需求。GOAL试验表明,通过单次门诊老年科医生预约实施综合老年评估,并未改善患有慢性肾脏病和衰弱的老年人的目标达成情况。需要评估综合老年评估和以人为本照护的其他模式。无论如何,拥抱以人为本照护应成为所有肾脏病服务设定的目标。
Kidney international IF 21.8 2026-10 PMID: 42760017
Frailty in children with chronic kidney disease remains poorly recognized compared with adults and manifests differently, as loss of developmental potential rather than functional decline. In this commentary, we highlight that pediatric frailty should be identified early through standardized, age-appropriate screening, enabling timely multidisciplinary intervention. Crucially, unlike in adults, childhood frailty may be reversible, offering a vital window to maximize developmental and growth potential, build resilience, and restore a near-normal childhood.
中文摘要:与成人相比,儿童慢性肾脏病中的衰弱仍认识不足,且表现不同,不是功能衰退,而是发育潜能的丧失。在这篇评论中,我们强调,儿童衰弱应通过标准化、适龄的筛查尽早识别,从而实现及时的多学科干预。关键的是,与成人不同,儿童期衰弱可能是可逆的,这提供了一个重要窗口,以最大化发育和生长潜能、建立韧性,并恢复接近正常的童年。
Kidney international IF 21.8 2026-10 PMID: 42760016
Frailty is a condition commonly associated with aging, characterized by functional and cognitive decline, increasing dependence, and early mortality, but it is rarely conceptualized in children. We present a caregivers' perspective on frailty in her daughter living with childhood chronic kidney disease, highlighting the repercussions of chronic kidney disease and treatment on physical and psychosocial functioning across critical developmental years. The cumulative consequences of the deficits ultimately impaired long-term life participation and quality of life. However, frailty is increasingly recognized as a dynamic condition with the potential to be slowed down, arrested, or, in some instances, even reversed. There is, therefore, a need to better understand frailty in children, define tools that are developmentally appropriate, and ultimately routinize the measure and management of frailty within pediatric chronic kidney disease care. Children with chronic kidney disease deserve the opportunity to grow, flourish, participate in life, and enter adulthood with the best possible quality of life.
中文摘要:衰弱是一种通常与衰老相关的状况,其特征为功能与认知衰退、依赖增加和早期死亡,但很少在儿童中被概念化。我们呈现一位照护者对患有儿童期慢性肾病的女儿衰弱的观点,强调慢性肾病及其治疗在关键发育年份对躯体和社会心理功能的影响。这些缺陷的累积后果最终损害了长期生活参与和生活质量。然而,衰弱日益被认为是一种动态状况,有可能被减缓、阻止,在某些情况下甚至可逆。因此,有必要更好地理解儿童衰弱,定义适合发育阶段的工具,并最终将衰弱的测量和管理在儿科慢性肾病照护中常规化。患有慢性肾病的儿童应当有机会成长、茁壮发展、参与生活,并以尽可能最佳的生活质量进入成年期。
Drugs IF 14.7 2026-10 PMID: 42625106
Baxdrostat (BAXFENDY™) is a first-in-class, highly selective and potent aldosterone synthase inhibitor being developed by AstraZeneca for the treatment of hypertension, chronic kidney disease (CKD) and primary aldosteronism, and for the prevention of heart failure. On 15 May 2026, baxdrostat received its first approval in the USA for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure (BP) in adults who are not adequately controlled on other agents. This article summarizes the milestones in the development of baxdrostat leading to this first approval for hypertension.
中文摘要:Baxdrostat(BAXFENDY™)是一种首创的、高选择性和强效的醛固酮合酶抑制剂,由阿斯利康开发,用于治疗高血压、慢性肾脏病(CKD)和原发性醛固酮增多症,以及预防心力衰竭。2026年5月15日,baxdrostat在美国获得首次批准,与其他抗高血压药物联合用于治疗高血压,以降低其他药物控制不佳的成人的血压(BP)。本文总结了baxdrostat开发中导致其首次获批用于高血压的里程碑事件。
Redox biology IF 16.2 2026-10 PMID: 42612422
Heart failure (HF) progression is closely linked to oxidative stress. 5-Oxoproline (5-OP), a product of glutathione degradation, is normally metabolized by 5-oxoprolinase (OPLAH) but accumulates when the gamma-glutamyl cycle is disrupted. Here, we investigated the clinical characteristics of circulating 5-OP, its proteomic correlates, and the associations to outcome in HF. In serum of 823 BIOSTAT-CHF patients, 5-OP was quantified by validated liquid chromatography-mass spectrometry and analyzed for associations with clinical outcomes. Proteomic correlates were identified across 355 OLINK proteins using stability selection with Minimax Concave Penalty regression. Mechanistic context was evaluated in a multi-comorbidity, large-animal cardio-kidney-metabolic (CKM) model with regional OPLAH assessment. Higher 5-OP was associated with worse renal function (eGFR declining across 5-OP tertiles, 67.9 to 60.2 mL/min/1.73 m2; p = 0.0012) and higher all-cause mortality (HR 1.55, 95% CI 1.11-2.17, p = 0.010). Per SD increase in log-5-OP, risk for the 2-year composite endpoint increased (HR 1.27, 95% CI 1.05-1.53), with broadly similar associations across CKD strata (interaction p = 0.63). TGF-α was the most robust proteomic correlate (π = 0.70; empirical permutation p = 0.001). In CKM swine, circulating 5-OP was elevated and renal cortical OPLAH protein, but not cardiac OPLAH, was selectively reduced, consistent with a renal contribution to systemic 5-OP elevation. Circulating 5-OP identifies HF patients at higher risk and is robustly associated with TGF-α. In a translational swine model, selective loss of renal cortical OPLAH provides tissue context supporting a renal contribution to systemic 5-OP elevation in cardiorenal syndrome.
中文摘要:心力衰竭(HF)的进展与氧化应激密切相关。5-氧代脯氨酸(5-OP)是谷胱甘肽降解产物,通常由5-氧代脯氨酸酶(OPLAH)代谢,但当γ-谷氨酰循环紊乱时会蓄积。本研究探讨了循环5-OP的临床特征、其蛋白质组学相关因素及其与HF结局的关联。在823例BIOSTAT-CHF患者血清中,采用经验证的液相色谱-质谱法对5-OP进行定量,并分析其与临床结局的关联。通过使用Minimax凹惩罚回归的稳定性选择,在355种OLINK蛋白中识别蛋白质组学相关因素。在多合并症大型动物心肾代谢(CKM)模型中评估机制背景,并进行区域OPLAH评估。较高的5-OP与较差的肾功能相关(eGFR随5-OP三分位升高而下降,从67.9降至60.2 mL/min/1.73 m2;p=0.0012),并与较高的全因死亡率相关(HR 1.55,95% CI 1.11-2.17,p=0.010)。log-5-OP每增加1个标准差,2年复合终点风险增加(HR 1.27,95% CI 1.05-1.53),且在不同CKD分层中关联大致相似(交互作用p=0.63)。TGF-α是最稳健的蛋白质组学相关因素(π=0.70;经验置换p=0.001)。在CKM猪模型中,循环5-OP升高,肾皮质OPLAH蛋白选择性减少,而心脏OPLAH未减少,这与肾脏对系统性5-OP升高的贡献一致。循环5-OP可识别风险较高的HF患者,并与TGF-α稳健相关。在转化猪模型中,肾皮质OPLAH的选择性缺失提供了组织背景,支持心肾综合征中肾脏对系统性5-OP升高的贡献。
JAMA internal medicine IF 26.3 2026-10-01 PMID: 42606884
Serologic immunity to hepatitis A virus (HAV) and hepatitis B virus (HBV) protects against acute infection and severe outcomes among high-risk groups; however, contemporary data on population-level immunity remain limited, especially in high-risk populations. To estimate the prevalence and factors associated with serologic immunity in the overall population and across high-risk subgroups, including those with chronic liver disease (CLD), chronic kidney disease, diabetes, and immunosuppression and pregnant people. This cross-sectional study used data from the National Health and Nutrition Examination Survey from January 2017 to August 2023 and included adults aged 20 years or older with available HAV and HBV serologic test results. Data were analyzed from January 3 to May 10, 2026. The primary outcomes were the prevalence of serologic immunity to HAV, defined by hepatitis A antibody positivity, and HBV, defined by hepatitis B surface antibody positivity, with vaccine-derived immunity specifically identified by surface antibody positivity in the absence of hepatitis B core antibodies. Data were weighted to generate nationally representative estimates of the US adult population. Multivariable survey-weighted logistic regression models were used to identify independent factors associated with viral hepatitis immunity. Among 13 514 individuals, representing an estimated 226.1 million US adults (mean [SE] age, 48.65 [0.40] years; 51.76% female), 39.5% (95% CI, 37.7%-41.3%) demonstrated serologic immunity to hepatitis A, corresponding to approximately 89.4 million individuals. For HBV, 27.1% (95% CI, 25.8%-28.4%) demonstrated serologic immunity, corresponding to approximately 61.3 million individuals, while vaccine-derived immunity was present in 25.2% (95% CI, 23.9%-26.5%). In adjusted models, HAV immunity was associated with younger age (eg, 20-29 vs ≥65 years: adjusted odds ratio [AOR], 0.51; 95% CI, 0.44-0.60); lower educational attainment (eg,
中文摘要:甲型肝炎病毒(HAV)和乙型肝炎病毒(HBV)的血清学免疫可在高危人群中预防急性感染和严重结局;然而,尤其是在高危人群中,关于人群水平免疫的最新数据仍然有限。本研究旨在估计总体人群以及高风险亚组中血清学免疫的流行率及相关因素,高风险亚组包括慢性肝病(CLD)、慢性肾病、糖尿病、免疫抑制者及孕妇。这项横断面研究使用了2017年1月至2023年8月美国国家健康与营养调查的数据,纳入20岁及以上且具有可用HAV和HBV血清学检测结果的成人。数据分析时间为2026年1月3日至5月10日。主要结局为HAV血清学免疫的流行率,定义为甲型肝炎抗体阳性;以及HBV血清学免疫的流行率,定义为乙型肝炎表面抗体阳性;其中疫苗诱导免疫特指在乙型肝炎核心抗体阴性的情况下表面抗体阳性。对数据进行加权以生成美国成人人口的全国代表性估计。使用多变量调查加权logistic回归模型识别与病毒性肝炎免疫相关的独立因素。在13514名个体中,代表约2.261亿美国成人(平均[SE]年龄48.65[0.40]岁;女性51.76%),39.5%(95%CI,37.7%-41.3%)具有甲型肝炎血清学免疫,对应约8940万人。对于HBV,27.1%(95%CI,25.8%-28.4%)具有血清学免疫,对应约6130万人,而疫苗诱导免疫为25.2%(95%CI,23.9%-26.5%)。在校正模型中,HAV免疫与较年轻年龄相关(例如,20-29岁对比≥65岁:校正比值比[AOR],0.51;95%CI,0.44-0.60);较低教育程度(例如,低于9年级对比大学毕业生及以上:AOR,0.32;95%CI,0.24-0.42);非西班牙裔黑人(AOR,1.67;95%CI,1.34-2.09)、墨西哥裔美国人(AOR,4.22;95%CI,3.42-5.21)、其他西班牙裔(AOR,2.01;95%CI,1.60-2.54)、非西班牙裔亚裔(AOR,3.03;95%CI,2.45-3.76)以及多种族或其他种族和族裔(AOR,1.36;95%CI,1.04-1.79);在美国境外出生(AOR,4.54;95%CI,3.74-5.52);以及肝病知晓(OR,1.65;95%CI,1.29-2.09)。肥胖与HAV免疫的较低odds相关(AOR,0.83;95%CI,0.72-0.96)。疫苗诱导的HBV免疫与较年轻年龄相关(例如,20-29岁对比≥65岁:AOR,0.18;95%CI,0.15-0.23)、女性(AOR,1.36;95%CI,1.18-1.56)、非西班牙裔亚裔(AOR,1.47;95%CI,1.17-1.86)和非西班牙裔黑人(AOR,1.15;95%CI,1.00-1.32)种族和族裔,以及较高教育程度(例如,低于9年级对比大学毕业生及以上:AOR,3.29;95%CI,2.35-4.61)。在高风险亚组中,HAV免疫率从代谢功能障碍相关酒精相关肝病的26.7%(95%CI,18.9%-34.4%)到慢性HBV感染的63.7%(95%CI,50.0%-77.4%)不等,而HBV疫苗诱导免疫率从慢性肾病的14.0%(95%CI,11.3%-16.6%)到妊娠期的38.6%(95%CI,28.0%-49.1%)不等。这项横断面研究发现,人群水平HAV和HBV血清学免疫不理想,且在多个高风险临床亚组中持续存在大量易感者。这些发现突出表明病毒性肝炎保护方面持续存在差距,并支持针对HAV和HBV采取有针对性、系统性的疫苗接种策略,尤其是在高风险人群中。
Diabetologia IF 10.4 2026-10 PMID: 42525138
The aim of this study was to determine whether cardiac autonomic neuropathy (CAN) is an independent risk factor for kidney function decline in type 1 diabetes mellitus over a 15 year follow-up period. Eighty seven participants with type 1 diabetes and eGFR >30 ml/min per 1.73 m2 underwent cardiovascular autonomic reflex testing at baseline. Renal data were retrieved at 4 year intervals over 15 years. Stratification of participants into Kidney Disease: Improving Global Outcomes (KDIGO) chronic kidney disease progression prognostic risk was done by using eGFR and urinary albumin/creatinine ratio (UACR). Longitudinal changes in eGFR and UACR were analysed using linear mixed-effects models with adjustment for potential confounders to determine whether CAN is an independent predictor of eGFR and UACR change over 15 years. At baseline, higher KDIGO risk category was associated with increased severity of CAN (r=0.38, p<0.001) and increase in UACR (p<0.001) compared with the lower risk group. Participants with established CAN at baseline exhibited greater mean (SD) eGFR decline of 14.8 (21.6) ml/min per 1.73 m2, compared with 3.1 (7.3) and 3.3 (7.4) ml/min per 1.73 m2 in the early stage and those without CAN (p=0.004). Mean (SD) increases in UACR were 0.4 (0.9), 11.3 (30.4) and 4 (8.9) mg/mmol for no CAN, early CAN and established CAN (p=0.03), respectively. After adjusting for potential confounders, baseline CAN was independently associated with both accelerated eGFR decline (p=0.018) and greater increases in UACR (p=0.002) over time. CAN is an independent predictor of both accelerated eGFR decline and increased albuminuria in type 1 diabetes. The study also explored the relationship between CAN and KDIGO prognostic risk in diabetic kidney disease, demonstrating that increased severity of CAN is associated with higher KDIGO prognostic risk.
中文摘要:本研究旨在确定在15年随访期内,心脏自主神经病变(CAN)是否为1型糖尿病患者肾功能下降的独立危险因素。87名eGFR>30 ml/min/1.73 m²的1型糖尿病参与者在基线时接受了心血管自主反射测试。在15年内每4年获取一次肾脏数据。通过使用eGFR和尿白蛋白/肌酐比值(UACR),按照肾脏病改善全球预后(KDIGO)慢性肾脏病进展预后风险对参与者进行分层。采用线性混合效应模型分析eGFR和UACR的纵向变化,并校正潜在混杂因素,以确定CAN是否为15年内eGFR和UACR变化的独立预测因素。在基线时,与较低风险组相比,较高的KDIGO风险类别与CAN严重程度增加(r=0.38,p<0.001)和UACR增加(p<0.001)相关。基线时已确诊CAN的参与者平均(SD)eGFR下降为14.8(21.6)ml/min/1.73 m²,而早期CAN和无CAN者分别为3.1(7.3)和3.3(7.4)ml/min/1.73 m²(p=0.004)。无CAN、早期CAN和已确诊CAN的UACR平均(SD)增加分别为0.4(0.9)、11.3(30.4)和4(8.9)mg/mmol(p=0.03)。在校正潜在混杂因素后,基线CAN与eGFR加速下降(p=0.018)和UACR随时间增加更多(p=0.002)均独立相关。CAN是1型糖尿病中eGFR加速下降和白蛋白尿增加的独立预测因素。本研究还探讨了CAN与糖尿病肾病中KDIGO预后风险之间的关系,表明CAN严重程度增加与更高的KDIGO预后风险相关。
Kidney international IF 21.8 2026-10 PMID: 42521017
The cardiovascular-kidney-metabolic framework recognizes the interconnected biological, clinical, and societal drivers of cardiovascular disease, chronic kidney disease, diabetes, and obesity. To advance an integrated perspective, aligned with the kidney community focus, the International Society of Nephrology convened an International Expert Forum, bringing together a global and multidisciplinary team of leaders in this field. This meeting report synthesizes key discussions spanning cardiovascular-kidney-metabolic risk stratification, lifestyle interventions, guideline-directed medical therapies, emerging late-stage therapeutics, and models of care delivery. Participants emphasized the importance of early, integrated case finding; long-term, joint kidney-cardiovascular risk assessment; and timely use of evidence-informed therapies to reduce kidney disease progression, kidney failure, and cardiovascular events. Persistent gaps, including therapeutic inertia, fragmented care, and global inequities in access to care, were highlighted, alongside promising multidisciplinary and system-level care models. Emerging therapies targeting residual risk further underscore the need for adaptive implementation strategies. Aligned with the International Society of Nephrology's mission, this forum represents a foundational step toward connecting disciplines, bridging evidence-to-practice gaps, and building global capacity to improve equitable cardiovascular-kidney-metabolic outcomes.
中文摘要:心血管-肾脏-代谢框架认识到心血管疾病、慢性肾脏病、糖尿病和肥胖之间相互关联的生物学、临床和社会驱动因素。为推进整合视角,并与肾脏领域关注点保持一致,国际肾脏病学会召集了一次国际专家论坛,汇聚该领域全球多学科领导者。本会议报告综合了关键讨论,涵盖心血管-肾脏-代谢风险分层、生活方式干预、指南导向的药物治疗、新兴的晚期治疗以及照护提供模式。与会者强调早期、整合的病例发现;长期、联合的肾脏-心血管风险评估;及时使用循证治疗以减少肾脏病进展、肾衰竭和心血管事件的重要性。会议还指出持续存在的差距,包括治疗惰性、照护碎片化和全球照护可及性不平等,同时介绍了有前景的多学科和系统层面照护模式。针对残余风险的新兴治疗进一步凸显了适应性实施策略的必要性。与国际肾脏病学会的使命一致,本次论坛是连接不同学科、弥合证据到实践差距以及建设全球能力以改善公平的心血管-肾脏-代谢结局的基础性一步。
Kidney international IF 21.8 2026-10 PMID: 42508612
Dapagliflozin improves kidney outcomes in patients with chronic kidney disease (CKD), yet the underlying mechanisms by which it exerts protective effects are not fully elucidated. Here, we applied plasma proteomics to identify proteins and pathways linked to CKD progression and examined which of these are modulated by dapagliflozin. We measured 3072 circulating plasma proteins (Olink, Uppsala, Sweden) in 2485 of the 4304 (57.7%) patients with CKD from the DAPA-CKD trial (eGFR 25-75 mL/min per 1.73 m2 and urinary albumin-to-creatinine ratio 200-5000 mg/g). Proteins associated with the composite kidney outcome (50% eGFR decline, kidney failure, and kidney death) and with dapagliflozin treatment were respectively identified by multivariable Cox proportional hazard regression and ANCOVA. Ingenuity pathway analysis was used to identify relevant molecular pathways and upstream regulators. Pathways that had the strongest association with the composite kidney outcome were hepatic fibrosis, insulin-like growth factor transport regulation, and tumor necrosis factor signaling. These pathways were generally related to fibrosis and inflammation. After 12 months, dapagliflozin treatment showed a (placebo-corrected) modification of 216 proteins, of which kidney injury molecule-1 showed the strongest reduction (-14.9%; 95% confidence interval: -17.9, -11.7). Of the 137 pathways associated with the kidney outcome, 35 (25%) were modified by dapagliflozin. Among these, activity of 11 (31% of 35) pathways decreased, and 10 (29% of 35) pathways were increased. Pathways associated with kidney outcome and modulated by dapagliflozin were related to extracellular matrix remodeling, inflammation and fibrosis, and immune-vascular interactions. This proteomic analysis reveals mechanisms underlying dapagliflozin's beneficial effects in CKD progression and shows that key pathways associated with CKD progression are modified by dapagliflozin, supporting its anti-inflammatory and antifibrotic potential.
中文摘要:达格列净可改善慢性肾脏病(CKD)患者的肾脏结局,但其发挥保护作用的潜在机制尚未完全阐明。在此,我们应用血浆蛋白质组学来识别与CKD进展相关的蛋白质和通路,并考察其中哪些可被达格列净调节。我们在DAPA-CKD试验4304例CKD患者中的2485例(57.7%)中检测了3072种循环血浆蛋白(Olink,瑞典乌普萨拉)(eGFR 25-75 mL/min/1.73 m2,尿白蛋白与肌酐比值200-5000 mg/g)。分别通过多变量Cox比例风险回归和ANCOVA识别与复合肾脏结局(eGFR下降50%、肾衰竭和肾脏死亡)相关的蛋白以及与达格列净治疗相关的蛋白。使用Ingenuity通路分析来识别相关分子通路和上游调节因子。与复合肾脏结局关联最强的通路为肝纤维化、胰岛素样生长因子转运调节和肿瘤坏死因子信号传导。这些通路通常与纤维化和炎症相关。12个月后,达格列净治疗显示对216种蛋白有(安慰剂校正的)调节作用,其中肾损伤分子-1的降低幅度最大(-14.9%;95%置信区间:-17.9,-11.7)。在与肾脏结局相关的137条通路中,有35条(25%)被达格列净调节。其中,11条(35条中的31%)通路活性下降,10条(35条中的29%)通路活性升高。与肾脏结局相关且受达格列净调节的通路与细胞外基质重塑、炎症和纤维化以及免疫-血管相互作用有关。这项蛋白质组学分析揭示了达格列净在CKD进展中获益的机制,并表明与CKD进展相关的关键通路可被达格列净调节,支持其抗炎和抗纤维化潜力。
Kidney international IF 21.8 2026-10 PMID: 42508611
While calcineurin inhibitors (CNIs) reduce proteinuria in a subgroup of children with genetic podocytopathies, previous reports suggest that the response is short-lived and of no benefit to long-term outcomes. Here, we assess CNI response sustainability and the association between different patterns of response preservation and kidney survival. We performed a retrospective cohort study of patients aged 0-18 years with genetic podocytopathies treated with CNIs for at least three months from 34 pediatric nephrology centers worldwide. Response status was defined in accordance with International Pediatric Nephrology Association Clinical Practice Recommendations. We analyzed 136 patients with genetic podocytopathies over a median follow-up period of 42.1 months (between CNI initiation and last follow-up or commencement of kidney replacement therapy, whichever occurred first). At least partial response was attained in 28% and 22% of patients at six months post-CNI initiation and last follow-up, respectively. Compared to no response group, patients with at least partial response at six months had significantly lower urine protein-to-creatinine ratios across various time points post-CNIs. 71%, 11% and 18% exhibited no response, non-sustained and sustained response, respectively, throughout the observation period. Both sustained and non-sustained responses were significantly associated with superior kidney survival compared to no response. Importantly, no patients with sustained response developed kidney failure over a follow-up period of 42 (interquartile range 19-62) months. Patients with non-sustained response had a 92% lower risk of kidney failure compared to non-responders. A subset of children with genetic podocytopathies experienced a sustained response to CNIs, and none developed kidney failure. Children with non-sustained response still demonstrated superior kidney survival compared to non-responders. Our findings may support a trial of CNIs in genetic podocytopathies, and continuing therapy among those showing clinical response.
中文摘要:虽然钙调神经磷酸酶抑制剂(CNIs)可减少部分遗传性足细胞病患儿的蛋白尿,但既往报告提示其反应短暂且对长期结局无益。在此,我们评估CNI反应的持续性以及不同反应维持模式与肾脏生存之间的关联。我们开展了一项回顾性队列研究,纳入来自全球34个儿童肾脏病中心、接受CNIs治疗至少3个月的0-18岁遗传性足细胞病患者。反应状态依据国际小儿肾脏病学会临床实践建议定义。我们分析了136例遗传性足细胞病患者,中位随访时间为42.1个月(从CNI开始至末次随访或开始肾脏替代治疗,以先发生者为准)。在CNI开始后6个月和末次随访时,分别有28%和22%的患者达到至少部分反应。与无反应组相比,6个月时达到至少部分反应的患者在CNI治疗后多个时间点的尿蛋白与肌酐比值显著更低。在整个观察期间,分别有71%、11%和18%表现为无反应、非持续反应和持续反应。与无反应相比,持续反应和非持续反应均与更优的肾脏生存显著相关。重要的是,在42个月(四分位距19-62)的随访期内,持续反应患者无一发生肾衰竭。非持续反应患者发生肾衰竭的风险比无反应者低92%。一部分遗传性足细胞病患儿对CNIs出现持续反应,且无一发生肾衰竭。非持续反应患儿的肾脏生存仍优于无反应者。我们的发现可能支持在遗传性足细胞病中试用CNIs,并对显示临床反应者继续治疗。
Kidney international IF 21.8 2026-10 PMID: 42498059
Alport syndrome (AS) is a hereditary glomerulopathy often associated with ocular abnormalities, yet structural retinal biomarkers remain underutilized in nephrology. Here, we evaluated the Temporal Thinning Index Maximum (TTIMax), a subject-level optical coherence tomography (OCT) metric, as a potential diagnostic biomarker for inherited podocytopathies. We evaluated TTIMax derived from OCT in 93 genetically confirmed patients with AS and 136 controls (84 with chronic kidney disease and 52 healthy individuals). Genetic diagnosis served as the reference standard and TTIMax as the index test. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis with calculation of sensitivity and specificity. TTIMax stratified disease severity across genotypes (severe X-linked AS-Male/autosomal recessive AS: 11.8%; intermediate X-linked AS-Female/autosomal dominant AS: 7.3-8.1%; controls: 5.3-5.8%) and remained significantly associated with disease severity after adjustment for age, eGFR, and blood pressure. ROC analysis demonstrated excellent discrimination for severe AS (area under the curve (AUC) 0.98; 95% Confidence Interval 0.96-1.00) with an optimal threshold of 8.4% (sensitivity 93%, specificity 99%). TTIMax distinguished severe AS from primary immune-mediated focal segmental glomerulosclerosis (FSGS) (AUC 0.97; 0.94-1.00) and differentiated COL4A-related FSGS from primary FSGS (AUC 0.91; 0.77-1.00). Longitudinal follow-up (four-14 years) demonstrated stability of TTIMax despite changes in kidney function. TTIMax provides a widely accessible, non-invasive structural biomarker that complements genetic testing and may aid in diagnosing inherited podocytopathies and interpreting COL4 variants of uncertain significance.
中文摘要:Alport综合征(AS)是一种遗传性肾小球病,常与眼部异常相关,但结构性视网膜生物标志物在肾脏病学中仍未得到充分利用。在此,我们评估了颞侧变薄指数最大值(TTIMax),一种受试者水平的光学相干断层扫描(OCT)指标,作为遗传性足细胞病潜在诊断生物标志物。我们在93例经基因确诊的AS患者和136例对照者(84例慢性肾脏病和52例健康个体)中评估了由OCT得出的TTIMax。遗传诊断作为参考标准,TTIMax作为指标试验。采用受试者工作特征(ROC)分析评估诊断性能,并计算敏感性和特异性。TTIMax可跨基因型对疾病严重程度进行分层(严重X连锁AS-男性/常染色体隐性AS:11.8%;中间型X连锁AS-女性/常染色体显性AS:7.3–8.1%;对照:5.3–5.8%),并且在调整年龄、eGFR和血压后仍与疾病严重程度显著相关。ROC分析显示其对严重AS具有极好的区分能力(曲线下面积(AUC)0.98;95%置信区间0.96–1.00),最佳阈值为8.4%(敏感性93%,特异性99%)。TTIMax可将严重AS与原发性免疫介导的局灶节段性肾小球硬化(FSGS)区分开来(AUC 0.97;0.94–1.00),并可将COL4A相关FSGS与原发性FSGS区分开来(AUC 0.91;0.77–1.00)。纵向随访(4–14年)显示,尽管肾功能发生变化,TTIMax仍保持稳定。TTIMax提供了一种广泛可及的非侵入性结构生物标志物,可补充基因检测,并可能有助于诊断遗传性足细胞病以及解读意义未明的COL4变异。
Kidney international IF 21.8 2026-10 PMID: 42498056
Serum creatinine is a commonly used biomarker for estimating glomerular filtration rate (eGFR), but is influenced by determinants unrelated to kidney function, including muscle mass, age, sex, diet, and genetic variation. Biological drivers of persistent eGFR bias in African ancestry populations remain understudied. Here, we investigated whether African-enriched genetic variation at the glycine amidinotransferase (GATM) locus, encoding the rate limiting enzyme in creatine biosynthesis, contributes to systematic bias in creatinine-based estimates of GFR. We analyzed whole-genome sequencing and phenotypic data from population-based cohorts in Uganda (5,760 individuals) and South Africa (827 individuals). Genome-wide association studies were integrated with expression quantitative trait locus and metabolomic analyses to characterize biological mechanisms. The iohexol measured GFR was used to quantify systematic bias for creatinine-based estimates (eGFRCr). Diagnostic implications were evaluated in African American participants of the Million Veteran Program. We described variants associated with eGFRCr at the GATM locus that were common in African populations (allele frequency about 50%) but rare or absent in Europeans. These variants explained 1.0%-1.7% of the variance in eGFRCr and were associated with increased GATM expression and enhanced creatine synthesis, resulting in higher serum creatinine and consequently lower eGFRCr. Each allele was associated with an approximately 2 ml/min per 1.73 m2 lower eGFRCr, and the association was independent of measured GFR, age, sex, and body composition. In contrast, these variants showed no association with measured GFR or cystatin C-based eGFR, supporting a biomarker-specific effect. In African American participants, GATM variants were associated with increased odds of a CKD diagnosis using eGFRCr thresholds but not with end-stage kidney disease. African-enriched GATM variants are associated with measurable bias in creatinine-based GFR estimation without evidence of altered kidney function. These findings improve understanding of differences in kidney function biomarkers and may be relevant when interpreting creatinine-based estimates, particularly in populations where the variant is common.
中文摘要:血清肌酐是估算肾小球滤过率(eGFR)的常用生物标志物,但会受到与肾功能无关的因素影响,包括肌肉量、年龄、性别、饮食和遗传变异。非洲裔人群中持续性eGFR偏倚的生物学驱动因素仍研究不足。在本研究中,我们探讨了甘氨酸脒基转移酶(GATM)位点上在非洲人群中富集的遗传变异是否导致基于肌酐的GFR估算出现系统性偏倚;GATM编码肌酸生物合成中的限速酶。我们分析了乌干达(5760人)和南非(827人)基于人群队列的全基因组测序和表型数据。将全基因组关联研究与表达数量性状位点及代谢组学分析整合,以刻画生物学机制。使用碘海醇测定的GFR来量化基于肌酐的估算值(eGFRCr)的系统性偏倚。在百万退伍军人计划中的非裔美国参与者中评估了诊断意义。我们描述了与eGFRCr相关的GATM位点变异,这些变异在非洲人群中常见(等位基因频率约50%),但在欧洲人中罕见或缺失。这些变异解释了eGFRCr变异的1.0%-1.7%,并与GATM表达增加和肌酸合成增强相关,导致血清肌酐升高,从而eGFRCr降低。每个等位基因与eGFRCr约降低2 ml/min/1.73 m2相关,并且该关联独立于测定的GFR、年龄、性别和身体成分。相反,这些变异与测定的GFR或基于胱抑素C的eGFR无关,支持生物标志物特异性效应。在非裔美国参与者中,GATM变异与使用eGFRCr阈值诊断CKD的比值增加相关,但与终末期肾病无关。非洲人群中富集的GATM变异与基于肌酐的GFR估算中可测量的偏倚相关,而没有肾功能改变的证据。这些发现增进了对肾功能生物标志物差异的理解,并且在解读基于肌酐的估算值时可能具有相关性,尤其是在该变异常见的群体中。
Pharmacology & therapeutics IF 13.5 2026-10 PMID: 42471062
Standard modifiable cardiovascular risk factors (SMuRFs) and non-SMuRFs are commonly used for risk stratification and therapeutic guidance after ST-elevation myocardial infarction (STEMI) in the general population. Their prognostic relevance with a potential implication for pharmacological and therapeutic management in individuals with established diabetes remains uncertain. This systematic review with meta-analysis aimed to identify prognostic factors associated with mortality in individuals with diabetes and STEMI qualifying for potential therapeutic targets. Studies evaluating prognostic factors for mortality in individuals with diabetes after STEMI were included up to May 3, 2025. Data extraction was performed independently by two reviewers. Certainty of evidence (CoE) was evaluated (GRADE). Thirty-seven studies were included, of which 25 had a high risk of bias. Mortality after STEMI in individuals with diabetes was consistently associated with non-SMuRFs (age, female sex, chronic kidney disease), acute cardiac dysfunction (Killip class III-IV, heart failure, cardiogenic shock), and atherosclerosis extent (anterior infarction, prior myocardial infarction, peripheral vascular disease). Diabetes-specific risk factors, including glycemic control parameters and insulin treatment, were also associated with increased risk of mortality (low to very low CoE). Once diabetes is established, no increased risk of mortality was observed for traditional SMuRFs, such as hypertension, smoking status, dyslipidemia, and obesity. These findings highlight the need for therapeutic strategies beyond conventional risk factor modification, with emphasis on acute hemodynamic management, tailored pharmacotherapy, and optimized glycemic control in this high-risk population. REGISTRATION PROSPERo: CRD42022378193.
中文摘要:标准可改变心血管危险因素(SMuRFs)和非标准可改变心血管危险因素(non-SMuRFs)常用于一般人群ST段抬高型心肌梗死(STEMI)后的风险分层和治疗指导。在已确诊糖尿病的个体中,这些因素与预后的相关性及其对药物和治疗管理的潜在意义仍不确定。本系统评价及荟萃分析旨在识别与糖尿病合并STEMI个体死亡相关的预后因素,这些因素可能符合潜在治疗靶点。纳入截至2025年5月3日评估糖尿病个体STEMI后死亡预后因素的研究。由两名评价者独立提取数据。评估证据确定性(CoE)(GRADE)。共纳入37项研究,其中25项存在高偏倚风险。糖尿病个体STEMI后死亡一致地与non-SMuRFs(年龄、女性、慢性肾脏病)、急性心功能障碍(Killip III-IV级、心力衰竭、心源性休克)以及动脉粥样硬化范围(前壁梗死、既往心肌梗死、外周血管疾病)相关。糖尿病特异性危险因素,包括血糖控制参数和胰岛素治疗,也与死亡风险增加相关(CoE低至极低)。一旦确诊糖尿病,传统SMuRFs如高血压、吸烟状况、血脂异常和肥胖未观察到死亡风险增加。这些发现强调,在这一高风险人群中,需要超越传统危险因素干预的治疗策略,重点包括急性血流动力学管理、个体化药物治疗和优化血糖控制。注册:PROSPERO:CRD42022378193。
Kidney international IF 21.8 2026-10 PMID: 42315016
Frail older adults with chronic kidney disease (CKD) often experience complex care needs that may benefit from a comprehensive geriatric assessment (CGA). Our GOAL trial evaluated whether an outpatient CGA could improve patient-centered goal attainment in this population. GOAL was an open-label, cluster-randomized controlled trial conducted across 15 Australian kidney outpatient centers from March 2021 to June 2023, with a 12-month follow-up. Centers randomized 1:1, delivered a single outpatient CGA plus usual care or usual care alone. Participants were aged 65 years and older (55 years and older for First Nations peoples) with moderate to severe CKD (eGFR 59 mL/min per 1.73 m2 and under) and frail (Frailty Index over 0.25). Of 771 screened, 240 were enrolled (mean age 76.9 years; median Frailty Index 0.39; 56% male), and 179 (74.6%) completed follow-up. In intervention centers, geriatricians performed a one-off CGA and provided individualized management plans. The primary outcome was goal attainment at three months, assessed using Goal Attainment Scaling (GAS), where a mean score of 50 or more indicates goal achievement. Mixed-effects linear regression was used for analysis. Secondary outcomes included quality of life, frailty status, mortality, hospitalizations, and residential aged care admission. All analyses were intention-to-treat at both cluster and participant levels. At three months, mean GAS scores were not significantly different between the intervention and control groups (45.2 vs 43.7; mean difference 1.54, 95% confidence interval: 3.13 to 6.20). No significant differences were found across secondary outcomes. A non-statistically significant reduction of 2.5 days in total hospital stay was observed in the intervention group. Outpatient CGA did not improve goal attainment or clinical outcomes in frail older adults with CKD. These findings do not support routine implementation of single-episode outpatient CGA in this setting and suggest a need for alternative, integrated models of person-centered care. Registered at ClinicalTrials.gov with study number NCT04538157.
中文摘要:患有慢性肾脏病(CKD)的衰弱老年人常存在复杂照护需求,可能从综合老年评估(CGA)中获益。我们的GOAL试验评估了门诊CGA能否改善该人群以患者为中心的目标达成情况。GOAL是一项开放标签、整群随机对照试验,于2021年3月至2023年6月在15个澳大利亚肾脏门诊中心开展,随访12个月。中心按1:1随机分组,分别提供单次门诊CGA加常规照护或单纯常规照护。参与者年龄为65岁及以上(原住民为55岁及以上),患有中重度CKD(eGFR为59 mL/min/1.73 m2及以下)且存在衰弱(衰弱指数超过0.25)。在771例接受筛查者中,240例被纳入(平均年龄76.9岁;衰弱指数中位数0.39;56%为男性),179例(74.6%)完成随访。在干预中心,老年医学专科医生实施一次性CGA并提供个体化管理计划。主要结局是3个月时的目标达成情况,采用目标达成量表(GAS)评估,平均分50分及以上表示目标达成。采用混合效应线性回归进行分析。次要结局包括生活质量、衰弱状态、死亡率、住院和入住养老机构。所有分析均在意向治疗原则下于整群和参与者两个层面进行。3个月时,干预组与对照组的平均GAS评分无显著差异(45.2对43.7;平均差1.54,95%置信区间:3.13至6.20)。次要结局均未发现显著差异。干预组总住院时间减少2.5天,但无统计学意义。门诊CGA未改善CKD衰弱老年人的目标达成或临床结局。这些发现不支持在该情境中常规实施单次门诊CGA,并提示需要替代性的、整合式的以人为本照护模式。已在ClinicalTrials.gov注册,研究编号NCT04538157。
Kidney international IF 21.8 2026-10 PMID: 42248560
The medical community has long recognized the role of kidney disease and its impact on overall health. This recognition was accompanied by acknowledging the need for guidelines that help standardize practice based on the best available evidence. More recently, kidney disease has been established as a global public health priority when the World Health Organization adopted the first-ever resolution focused on kidney health. Kidney Disease: Improving Global Outcomes (KDIGO) was established, more than 2 decades ago, to address this need. As KDIGO adapts its processes to meet the needs of a rapidly changing landscape, its strong commitment to transparency, inclusivity, and integrity in developing trustworthy guidelines based on the best available evidence persists. In this 7-article series about the KDIGO life cycle of guideline development, we highlight a few aspects in the KDIGO guideline process. We also address areas that are frequently asked about by KDIGO end users and stakeholders (also known as interest holders). In this first article, we introduce the KDIGO guideline development process and summarize the different KDIGO products and deliverables.
中文摘要:医学界长期以来已认识到肾脏疾病的作用及其对整体健康的影响。这种认识也伴随着对指南需求的认可,即指南有助于基于最佳可得证据来规范实践。更近期,当世界卫生组织通过了首个聚焦肾脏健康的决议时,肾脏疾病已被确立为全球公共卫生优先事项。肾脏病:改善全球预后(KDIGO)于20多年前成立,以应对这一需求。随着KDIGO调整其流程以适应快速变化的格局需求,其基于最佳可得证据制定值得信赖指南时对透明、包容和诚信的坚定承诺始终不变。在这个关于KDIGO指南开发生命周期的7篇文章系列中,我们重点介绍KDIGO指南流程中的若干方面。我们也讨论KDIGO最终用户和利益相关者(也称为利益持有人)经常询问的领域。在本第一篇中,我们介绍KDIGO指南制定流程,并总结KDIGO的不同产品和交付成果。
Journal of the American Academy of Dermatology IF 12.3 2026-10 PMID: 40543664
Chronic kidney disease (CKD) affects 10% of the world's population and 1 in 7 adults in the United States. Dermatologic manifestations are common in CKD patients and are often challenging to diagnose and treat due to a broad differential diagnosis and lack of consensus guidelines. Prompt recognition of dermatologic disease is crucial for timely management and avoidance of complications. In part 1 of this 2-part continuing medical education series, we review dermatologic manifestations affecting CKD patients. Herein, we discuss epidemiology, clinical and histopathological presentations, and management of common and unique dermatoses affecting this population, including CKD-associated pruritus, pigmentary changes, uremic frost, porphyria cutanea tarda, acquired perforating disorders, and hair and nail changes.
中文摘要:慢性肾脏病(CKD)影响全球10%的人口,在美国每7名成人中就有1人患病。CKD患者常出现皮肤表现,且由于鉴别诊断广泛且缺乏共识指南,这些表现往往难以诊断和治疗。及时识别皮肤病对于及时处理和避免并发症至关重要。在这篇由两部分组成的继续医学教育系列文章的第一部分中,我们回顾了影响CKD患者的皮肤表现。本文讨论了影响该人群的常见和独特皮肤病的流行病学、临床与组织病理学表现及管理,包括CKD相关瘙痒、色素改变、尿毒霜、迟发性皮肤卟啉病、获得性穿通性疾病以及毛发和指甲改变。

基础研究 (4篇)

Ageing research reviews IF 15.5 2026-10-07 PMID: 42843465
The cardio-renal-hepatic-metabolic (CRHM) axis represents the bidirectional network through which cardiovascular disease, chronic kidney disease, metabolic dysfunction, and liver disorders propagate injury across organs. Within this network, Klotho has emerged as a context-dependent regulator linking mineral metabolism, metabolic homeostasis, cellular stress, inflammation, and tissue remodelling. Klotho comprises distinct signalling axes: the renal α-Klotho-Fibroblast growth factor (FGF)-23 axis, which governs mineral metabolism, and the hepatic β-Klotho-FGF19/FGF21 axis, regulating energy homeostasis. Declining Klotho availability, particularly with ageing and chronic disease, is associated with excess FGF23, disordered phosphate and vitamin D metabolism, oxidative stress, inflammation, and fibrotic remodelling. Collectively, these contribute to cardiac hypertrophy, vascular calcification, hepatic steatosis, insulin resistance, and progressive renal dysfunction. Importantly, Klotho biology is influenced by tissue context, isoform, disease stage, age and sex. However, human evidence remains largely associative and is derived predominantly from observational studies, and meta-analyses have not established causality. As a biomarker, circulating Klotho faces challenges of assay variability, isoform complexity, and age- and sex-dependent interpretation. Therapeutic strategies, established pharmacological interventions, exercise, recombinant Klotho, Klotho-derived peptides, and gene-based approaches have shown encouraging preclinical and biomarker studies. Still, clinical translation awaits standardized assays, longitudinal cohorts, and mechanism-based randomized trials. Klotho should therefore be viewed as a dynamic marker and modulator of CRHM network integrity, whose significance depends on tissue context, isoform, and disease stage.
中文摘要:心-肾-肝-代谢(CRHM)轴代表一个双向网络,心血管疾病、慢性肾脏病、代谢功能障碍和肝脏疾病通过该网络在器官之间传播损伤。在该网络中,Klotho 已成为一种依赖情境的调节因子,连接矿物质代谢、代谢稳态、细胞应激、炎症和组织重塑。Klotho 包含不同的信号轴:肾脏 α-Klotho-成纤维细胞生长因子(FGF)-23 轴调控矿物质代谢,肝脏 β-Klotho-FGF19/FGF21 轴调节能量稳态。Klotho 可用性下降,尤其是在衰老和慢性疾病中,与 FGF23 过量、磷酸盐和维生素 D 代谢紊乱、氧化应激、炎症和纤维化重塑相关。总体而言,这些因素促成心脏肥大、血管钙化、肝脂肪变性、胰岛素抵抗和进行性肾功能障碍。重要的是,Klotho 生物学受组织情境、亚型、疾病阶段、年龄和性别影响。然而,人类证据在很大程度上仍是关联性的,主要来自观察性研究,荟萃分析尚未确立因果关系。作为生物标志物,循环 Klotho 面临检测方法变异、亚型复杂性以及年龄和性别依赖性解读等挑战。治疗策略、已确立的药物干预、运动、重组 Klotho、Klotho 衍生肽和基于基因的方法已在临床前和生物标志物研究中显示出令人鼓舞的结果。尽管如此,临床转化仍需要标准化检测、纵向队列和基于机制的随机试验。因此,Klotho 应被视为 CRHM 网络完整性的动态标志物和调节因子,其意义取决于组织情境、亚型和疾病阶段。
ACS sensors IF 10.9 2026-10-07 PMID: 42842638
High-performance room-temperature ammonia (NH3) sensors are highly desirable for environmental monitoring and noninvasive chronic kidney disease diagnosis via breath analysis. Structurally advantageous, metal-organic framework (MOF)-derived metal oxides combined with low-cost, highly catalytic, nonprecious high-entropy alloy (HEA) nanoparticles show great potential for room-temperature gas sensing, yet such composites are rarely explored. Herein, FeCoNiMnCu HEA was rationally coupled with MOF-derived porous In2O3 to fabricate a HEA-modified In2O3 (HEA-IO) composite for room-temperature NH3 sensing. The optimized HEA-IO sensor delivered exceptional anti-interference selectivity and achieved a sensing response of 98.3 to 80 ppm NH3, almost twenty-fold that of pristine MOF-derived In2O3 and other control samples. Furthermore, it also featured rapid response/recovery speed, a low detection limit, humidity resistance, and excellent long-term stability. DFT calculations confirmed that FeCoNiMnCu HEA optimized surface electronic states, promoted NH3 enrichment and catalytic reactions, and accelerated interfacial charge transfer. Raman and TPD characterizations corroborated a unique interfacial synergistic interaction between HEA and MOF-derived In2O3, which was absent in conventional In2O3-based counterparts. The synergistic effect endowed HEA-IO with superior room-temperature NH3 sensing capabilities, enabling promising breath biomarker detection in clinical noninvasive diagnosis.
中文摘要:高性能室温氨气(NH3)传感器对于环境监测以及通过呼气分析进行无创慢性肾病诊断具有重要需求。金属有机框架(MOF)衍生的金属氧化物具有结构优势,将其与低成本、高催化活性、非贵金属高熵合金(HEA)纳米颗粒相结合,在室温气体传感方面展现出巨大潜力,然而此类复合材料鲜有探索。本文合理地将FeCoNiMnCu HEA与MOF衍生的多孔In2O3耦合,制备了HEA修饰的In2O3(HEA-IO)复合材料,用于室温NH3传感。优化后的HEA-IO传感器具有优异的抗干扰选择性,对80 ppm NH3的传感响应达到98.3,几乎是原始MOF衍生In2O3和其他对照样品的二十倍。此外,它还具有快速的响应/恢复速度、低检测限、抗湿性和优异的长期稳定性。DFT计算证实,FeCoNiMnCu HEA优化了表面电子态,促进了NH3富集和催化反应,并加速了界面电荷转移。拉曼和程序升温脱附表征证实了HEA与MOF衍生In2O3之间存在独特的界面协同相互作用,而传统基于In2O3的对应材料中不存在这种作用。该协同效应赋予HEA-IO优异的室温NH3传感能力,有望用于临床无创诊断中的呼气生物标志物检测。
European heart journal IF 45.3 2026-10-06 PMID: 42834001
Vascular calcification predicts cardiovascular mortality more strongly than traditional risk factors, yet its molecular basis remains poorly understood. The burden is greatest in chronic kidney disease (CKD), where disordered mineral metabolism accelerates arterial mineral deposition. Cross-trait genome-wide and phenome-wide association analyses were combined with single-cell RNA-seq and ATAC-seq from human kidneys and coronary arteries to identify upstream regulators. Chromatin immunoprecipitation sequencing and expression profiling were used to assess direct transcriptional control. Functional relevance was evaluated in multiple gene-edited mouse lines and in primary vascular smooth muscle cells (VSMCs) targeting T-box transcription factor 2 (TBX2), Runt-related transcription factor 2 (RUNX2), NLRP3, CASP1, and GSDMD. GWAS followed by expression quantitative trait loci (eQTL) and Bayesian colocalization analysis prioritized TBX2 as a shared genetic locus associated with kidney function and calcification-related cardiometabolic traits. TBX2-deficient mice exhibited increased susceptibility to vascular calcification, hypercalciuria, kidney injury, bone demineralization, and systemic phosphate dysregulation under CKD-like phosphate stress conditions. TBX2 deficiency promoted VSMC calcification and osteochondrogenic differentiation in vitro. Mechanistically, TBX2 acted as a transcriptional repressor by binding the promoter of RUNX2, a key osteogenic transcription factor, and suppressing its expression. Deletion of RUNX2 in TBX2-deficient VSMCs abolished TBX2 loss-induced calcification. TBX2-deficient VSMCs were also more sensitive to activation of the NLRP3 inflammasome by microcrystals generated from osteogenic VSMCs. Genetic deletion of NLRP3, CASP1, or GSDMD in TBX2-deficient mice attenuated vascular calcification and renal injury. In human samples, TBX2 expression inversely correlated with the severity of kidney fibrosis and was reduced in calcified vascular lesions. Integrative genetic, cellular, and animal studies identify TBX2 as a central transcriptional repressor linking mineral dysregulation, osteogenic signalling, and sterile inflammation in CKD-associated vascular calcification. Therapeutic strategies that restore TBX2 function or target its RUNX2-NLRP3 axis may reduce cardiovascular risk in patients with CKD.
中文摘要:血管钙化对心血管死亡的预测能力强于传统危险因素,但其分子基础仍了解甚少。该负担在慢性肾脏病(CKD)中最为突出,此时矿物质代谢紊乱会加速动脉矿物质沉积。研究将跨性状全基因组关联分析和全表型关联分析与来自人肾脏和冠状动脉的单细胞RNA测序及ATAC测序相结合,以识别上游调控因子。采用染色质免疫沉淀测序和表达谱分析评估直接转录调控。在多种基因编辑小鼠品系以及靶向T-box转录因子2(TBX2)、Runt相关转录因子2(RUNX2)、NLRP3、CASP1和GSDMD的原代血管平滑肌细胞(VSMC)中评估功能相关性。GWAS后进行的表达数量性状位点(eQTL)和贝叶斯共定位分析将TBX2优先列为与肾功能及钙化相关心脏代谢性状相关的共享遗传位点。TBX2缺陷小鼠在类似CKD的磷酸盐应激条件下表现出对血管钙化、高钙尿、肾损伤、骨脱矿和全身磷酸盐失调的易感性增加。TBX2缺陷在体外促进VSMC钙化和成骨软骨源性分化。机制上,TBX2通过结合关键成骨转录因子RUNX2的启动子并抑制其表达,发挥转录抑制因子作用。在TBX2缺陷的VSMC中敲除RUNX2可消除TBX2缺失诱导的钙化。TBX2缺陷的VSMC对由成骨性VSMC产生的微晶体激活NLRP3炎症小体也更敏感。在TBX2缺陷小鼠中遗传性敲除NLRP3、CASP1或GSDMD可减轻血管钙化和肾损伤。在人类样本中,TBX2表达与肾纤维化严重程度呈负相关,并在钙化血管病变中降低。整合遗传、细胞和动物研究确定TBX2是连接矿物质失调、成骨信号和无菌性炎症在CKD相关血管钙化中的核心转录抑制因子。恢复TBX2功能或靶向其RUNX2-NLRP3轴的治疗策略可能降低CKD患者的心血管风险。
Kidney international IF 21.8 2026-10 PMID: 42486192
Cadherin-11 (CDH11) is a mechanosensitive protein capable of creating cell-cell and cell-substrate junctions governing responses to environmental stimuli. It is known to perpetuate fibroblast activation and an inflammatory environment, so we hypothesized that CDH11 is a viable target to suppress kidney injury. Three models were used to test the efficacy of Cdh11 ablation and the CDH11 blocking antibody SYN0012 on kidney injury outcomes: unilateral ureteral obstruction, aristolochic acid nephropathy, and uninephrectomy with angiotensin II infusion. Kidney fibroblasts were isolated to test CDH11-mediated response to environmental cues. Cytokine arrays were used to quantify secretory changes, and atomic force microscopy was used to measure tissue stiffness. CDH11 increased after injury and was localized to the interstitium. Cdh11-/- mice had reduced fibrosis and decreased circulating levels of inflammatory, fibrotic, and kidney injury markers after unilateral ureteric obstruction. Cdh11-/- mice had improved survival and kidney function (plasma BUN) in the aristolochic acid nephropathy model, while in the uninephrectomy model with angiotensin II infusion, Cdh11-/- mice had improved function and muted cardiorenal injury markers. Contractility and sensitivity to strain in Cdh11-/- kidney fibroblasts were decreased, and these effects are further supported by limited tissue stiffening of the fibrogenic niche after unilateral ureteric obstruction. SYN0012 recapitulated the major findings in all three injury models. Targeting CDH11 attenuates kidney injury in multiple models to improve kidney function, decrease fibrosis and inflammation, and protect from downstream cardiac remodeling. This establishes CDH11 as a major player in renal fibroblast mechanobiology, limiting tissue stiffening and therefore propagation of injury. Hence, CDH11 targeting may be a novel strategy to limit expansion of chronic kidney disease.
中文摘要:Cadherin-11(CDH11)是一种机械敏感蛋白,能够形成细胞-细胞和细胞-基质连接,从而调控对环境刺激的反应。已知其可维持成纤维细胞活化及炎症环境,因此我们假设CDH11是抑制肾损伤的可行靶点。我们使用三种模型来检验Cdh11缺失和CDH11阻断抗体SYN0012对肾损伤结局的疗效:单侧输尿管梗阻、马兜铃酸肾病,以及单侧肾切除联合血管紧张素II输注。分离肾脏成纤维细胞以检测CDH11介导的对环境线索的反应。使用细胞因子芯片量化分泌变化,并使用原子力显微镜测量组织硬度。损伤后CDH11增加,并定位于间质。在单侧输尿管梗阻后,Cdh11-/-小鼠纤维化减少,循环中炎症、纤维化和肾损伤标志物水平降低。在马兜铃酸肾病模型中,Cdh11-/-小鼠生存率和肾功能(血浆BUN)改善;而在单侧肾切除联合血管紧张素II输注模型中,Cdh11-/-小鼠功能改善,心肾损伤标志物减弱。Cdh11-/-肾脏成纤维细胞的收缩性和对机械应变的敏感性降低,单侧输尿管梗阻后促纤维化微环境组织硬化有限也进一步支持这些效应。SYN0012在三种损伤模型中再现了主要发现。靶向CDH11可在多种模型中减轻肾损伤,改善肾功能,减少纤维化和炎症,并防止下游心脏重构。这确立了CDH11在肾脏成纤维细胞机械生物学中的主要作用,其限制组织硬化,从而限制损伤传播。因此,靶向CDH11可能成为限制慢性肾脏病进展的新策略。

2急性肾损伤 AKI (10篇)

临床研究 (6篇)

American journal of respiratory and critical care medicine IF 21.7 2026-10-07 PMID: 42842391
Among adults hospitalized with acute infection, a recent randomized trial observed no significant average treatment effect of cefepime versus piperacillin-tazobactam on acute kidney injury or death, but fewer days-alive-and-free-of delirium and coma with cefepime. To determine whether patients' individual characteristics modify the effect of cefepime versus piperacillin-tazobactam on outcomes. In this secondary analysis of the Antibiotic Choice On Renal Outcomes (ACORN) trial, an effect model was derived and validated to predict the effect of cefepime versus piperacillin-tazobactam for adults hospitalized with acute infection. The primary outcome was survival without acute kidney injury; the secondary outcome was survival without delirium or coma. The individualized treatment effect predicted in the validation cohort significantly modified the effect of cefepime versus piperacillin-tazobactam on survival without acute kidney injury (Qini 1.68; 95% confidence interval [CI], 0.25-3.18; p-value = 0.01). Among 626 patients predicted to experience ≥5% benefit from cefepime, 81.2% of patients randomized to cefepime survived without acute kidney injury, versus 74.2% randomized to piperacillin-tazobactam (difference, 7.1%; 95%CI, 0.25 to 13.9%). Among 203 patients predicted to experience ≥5% benefit from piperacillin-tazobactam, 56.6% of patients randomized to cefepime survived without acute kidney injury, versus 63.0% randomized to piperacillin-tazobactam (difference, -6.3%; 95%CI, -20.7 to 8.2%). The effect of trial group on survival without delirium or coma was not modified by individual characteristics. Patients' individual characteristics modified the effect of cefepime versus piperacillin-tazobactam on survival without acute kidney injury but not on survival without delirium or coma.
中文摘要:在因急性感染住院的成人中,近期一项随机试验观察到,与哌拉西林-他唑巴坦相比,头孢吡肟对急性肾损伤或死亡的总体平均治疗效果无显著差异,但头孢吡肟组无谵妄和昏迷的存活天数更多。旨在确定患者个体特征是否会改变头孢吡肟与哌拉西林-他唑巴坦对结局的影响。在这项抗生素选择对肾脏结局(ACORN)试验的二次分析中,推导并验证了一个效应模型,用于预测头孢吡肟与哌拉西林-他唑巴坦对因急性感染住院成人的效应。主要结局为无急性肾损伤生存;次要结局为无谵妄或昏迷生存。在验证队列中预测的个体化治疗效应显著改变了头孢吡肟与哌拉西林-他唑巴坦对无急性肾损伤生存的效应(Qini 1.68;95%置信区间[CI],0.25-3.18;p值=0.01)。在626例预测从头孢吡肟获益≥5%的患者中,随机分配到头孢吡肟的患者中有81.2%无急性肾损伤生存,而随机分配至哌拉西林-他唑巴坦的患者为74.2%(差异,7.1%;95%CI,0.25至13.9%)。在203例预测从哌拉西林-他唑巴坦获益≥5%的患者中,随机分配到头孢吡肟的患者中有56.6%无急性肾损伤生存,而随机分配至哌拉西林-他唑巴坦的患者为63.0%(差异,-6.3%;95%CI,-20.7至8.2%)。试验分组对无谵妄或昏迷生存的效应未受到个体特征的改变。患者的个体特征改变了头孢吡肟与哌拉西林-他唑巴坦对无急性肾损伤生存的效应,但未改变对无谵妄或昏迷生存的效应。
Stroke IF 11.1 2026-10-01 PMID: 42817886
Contrast-associated acute kidney injury (CA-AKI) after endovascular thrombectomy (EVT) worsens outcomes in acute ischemic stroke, but threshold-based definitions do not capture prognostic information from subthreshold changes. We tested whether early creatinine change within 48 hours of EVT conveys graded prognostic information beyond dichotomous CA-AKI. We performed a secondary analysis of the CAN-REST (Contrast-Associated Nephropathy After Endovascular Stroke Treatment; REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06596603) registry, a retrospective multicenter observational cohort study of 6638 EVT-treated adults with acute ischemic stroke enrolled at 73 centers in 16 countries between January 1 and December 31, 2023. Early creatinine change was quantified as the natural logarithm ratio of 48-hour creatinine to baseline creatinine (ln[48-hour/baseline creatinine]), with CA-AKI defined per Kidney Disease: Improving Global Outcomes criteria (≥0.3 mg/dL or ≥1.5× baseline rise within 48 hours). Multivariable logistic regression adjusted for prespecified baseline and periprocedural covariates examined associations with 90-day modified Rankin Scale shift and in-hospital mortality; linear versus restricted cubic spline specification was selected by likelihood ratio testing, and contrasts were estimated at ±10%, ±25%, and ±50%. Greater creatinine worsening within 48 hours of EVT was independently associated with an unfavorable 90-day modified Rankin Scale shift (adjusted common odds ratio per 1-unit log-ratio increase, 1.48 [95% CI, 1.07-2.04]; linear) and in-hospital mortality (nonlinear dose-response, of larger magnitude). A 10% increase in creatinine at 48 hours-well below Kidney Disease: Improving Global Outcomes threshold-was associated with worse functional outcome (adjusted common odds ratio, 1.04 [95% CI, 1.01-1.07]) and death (adjusted odds ratio, 1.22 [95% CI, 1.13-1.32]); a 10% decrease in creatinine at 48 hours was associated with lower odds of both outcomes (adjusted common odds ratio, 0.96 [95% CI, 0.93-0.99] and 0.74 [95% CI, 0.65-0.86]). The functional-outcome association concentrated at upper modified Rankin Scale cut-points (severe disability, death); effect modification by baseline renal function was not significant. Early creatinine change after EVT conveys graded, outcome-specific prognostic information extending below formal CA-AKI thresholds, with a dose-response detectable at changes as modest as ±10%, complementing binary CA-AKI as a framework for post-EVT renal risk assessment. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06596603.
中文摘要:血管内血栓切除术(EVT)后发生造影剂相关急性肾损伤(CA-AKI)会恶化急性缺血性卒中结局,但基于阈值的定义无法捕捉阈下变化的预后信息。我们检验了EVT后48小时内早期肌酐变化是否在二分法CA-AKI之外提供分级预后信息。我们对CAN-REST(血管内卒中治疗后造影剂相关肾病;注册信息:网址:https://www.clinicaltrials.gov;唯一标识:NCT06596603)登记研究进行了二次分析,该研究是一项回顾性多中心观察性队列研究,纳入2023年1月1日至12月31日期间在16个国家73个中心登记的6638例接受EVT治疗的急性缺血性卒中成人。早期肌酐变化量化为48小时肌酐与基线肌酐的自然对数比值(ln[48小时/基线肌酐]),CA-AKI按肾脏病:改善全球预后标准定义(48小时内升高≥0.3 mg/dL或≥1.5倍基线)。采用多变量logistic回归,并校正预设基线及围手术期协变量,分析其与90天改良Rankin量表移位和院内死亡率的关联;通过似然比检验选择线性或限制性立方样条设定,并在±10%、±25%和±50%处估计对比。EVT后48小时内肌酐恶化程度越大,与不利的90天改良Rankin量表移位独立相关(每增加1单位对数比值,校正共同优势比1.48[95%CI,1.07-2.04];线性)和院内死亡率相关(非线性剂量-反应,幅度更大)。48小时肌酐升高10%——远低于肾脏病:改善全球预后阈值——与更差的功能结局(校正共同优势比,1.04[95%CI,1.01-1.07])和死亡(校正优势比,1.22[95%CI,1.13-1.32])相关;48小时肌酐降低10%与两种结局的更低优势比相关(校正共同优势比,0.96[95%CI,0.93-0.99]和0.74[95%CI,0.65-0.86])。功能结局关联集中于改良Rankin量表较高的切点(严重残疾、死亡);基线肾功能对该关联的效应修饰不显著。EVT后早期肌酐变化可提供分级的、结局特异性的预后信息,其范围延伸至正式CA-AKI阈值以下,在低至±10%的变化即可检测到剂量-反应,可作为EVT后肾脏风险评估框架中二分类CA-AKI的补充。网址:https://www.clinicaltrials.gov;唯一标识:NCT06596603。
Intensive care medicine IF 22.0 2026-10 PMID: 42578996
The optimal timing of adjunctive vasopressin after norepinephrine escalation in septic shock remains uncertain. We emulated a target trial comparing ultra-early vasopressin initiation within 0-3 h with early initiation within > 3-6 h after the norepinephrine infusion rate reached 0.25 μg/kg/min or higher. We emulated a target trial using electronic health record databases (MIMIC-IV 2008-2022 and eICU-CRD 2014-2015). Adults with septic shock who reached the norepinephrine threshold before vasopressin use were eligible. We used the clone-censor-weight method to estimate cumulative incidence curves under the ultra-early and early initiation strategies and compared them via the weighted Cox model. Among 3810 eligible patients, after cloning, 744 clones adhered to the ultra-early strategy and 293 clones adhered to the early strategy. The weighted 28-day mortality risk was 48.1% under the ultra-early strategy and 53.0% under the early strategy (risk difference, - 5.0 percentage points; 95% confidence interval [CI] - 6.8 to - 3.2), with a restricted mean survival time difference of 1.58 days (95% CI 1.21-1.92) and a hazard ratio (HR) of 0.82 (95% CI 0.78-0.85). Ultra-early initiation was associated with lower renal replacement therapy (HR, 0.68; 95% CI 0.63-0.74), continuous renal replacement therapy (HR, 0.61; 95% CI 0.55-0.68), and medically treated arrhythmia (HR, 0.91; 95% CI 0.83-0.99), but not with lower acute kidney injury. Among adults with septic shock whose norepinephrine infusion reached 0.25 μg/kg/min or higher before vasopressin use, vasopressin initiation within 0-3 h was associated with lower 28-day mortality than initiation within > 3-6 h.
中文摘要:在脓毒症休克中,去甲肾上腺素升级后辅助性血管加压素的最佳启动时机仍不确定。我们模拟了一项目标试验,比较在去甲肾上腺素输注速率达到0.25 μg/kg/min或更高后0-3小时内超早期启动血管加压素与>3-6小时内早期启动血管加压素。我们利用电子健康记录数据库(MIMIC-IV 2008-2022和eICU-CRD 2014-2015)模拟了一项目标试验。纳入在使用血管加压素前达到去甲肾上腺素阈值的成人脓毒症休克患者。我们使用克隆-删失-加权方法估计超早期和早期启动策略下的累积发生率曲线,并通过加权Cox模型进行比较。在3810例符合条件的患者中,克隆后,744个克隆遵循超早期策略,293个克隆遵循早期策略。超早期策略下的加权28天死亡风险为48.1%,早期策略下为53.0%(风险差为-5.0个百分点;95%置信区间[CI]为-6.8至-3.2),限制性平均生存时间差为1.58天(95% CI 1.21-1.92),风险比(HR)为0.82(95% CI 0.78-0.85)。超早期启动与较低的肾脏替代治疗(HR,0.68;95% CI 0.63-0.74)、连续性肾脏替代治疗(HR,0.61;95% CI 0.55-0.68)和药物治疗的心律失常(HR,0.91;95% CI 0.83-0.99)相关,但与较低的急性肾损伤无关。在血管加压素使用前去甲肾上腺素输注达到0.25 μg/kg/min或更高的成人脓毒症休克患者中,0-3小时内启动血管加压素与>3-6小时内启动相比,28天死亡率较低。
British journal of anaesthesia IF 10.3 2026-10 PMID: 42538266
Intraoperative norepinephrine is associated with postoperative acute kidney injury (AKI), but bedside-readable dose anchors remain undefined. We investigated the dose-response relationship between intraoperative norepinephrine and AKI, and its interaction with intraoperative hypotension. We analysed 27 874 surgical cases from the Medical Informatics Operating Room Vitals and Events Repository. The primary exposure was intraoperative norepinephrine dose, expressed as norepinephrine base (μg kg-1 min-1). The primary outcome was AKI within 7 postoperative days. The maximum dose, time-weighted intensity, duration, and area under the curve (AUC) were evaluated using restricted cubic splines and tensor-product generalised additive models, with multivariable mixed-effects logistic regression with a directed acyclic graph-derived adjustment set. Norepinephrine was administered in 1232 patients (4.4%), and AKI occurred in 4448 (16.0%). Restricted cubic spline analyses showed significant nonlinearity for unit-rate metrics (maximum dose P=0.008; time-weighted intensity P=0.022), whereas time-integrated metrics were linear (AUC P=0.10; duration P=0.50). Two bedside-readable anchors for maximum norepinephrine dose were identified at 0.029 and 0.064 μg kg-1 min-1. Dose-duration (P=0.286) and dose-hypotension interactions (P=0.298) were non-significant, supporting additive effects. A maximum norepinephrine dose of >0.029 μg kg-1 min-1 remained independently associated with AKI (odds ratio [OR] 1.76; 95% confidence interval [CI] 1.41-2.20; P<0.001); adjustment for intraoperative hypotension minimally attenuated this association (5.1%; adjusted OR 1.71; 95% CI 1.36-2.15). Intraoperative norepinephrine exposure was independently associated with postoperative AKI, with nonlinear behaviour for unit-rate metrics and linear behaviour for time-integrated metrics, largely independent of intraoperative hypotension. The two anchors define a two-tier vigilance framework.
中文摘要:术中去甲肾上腺素与术后急性肾损伤(AKI)相关,但可供床旁读取的剂量锚点仍未明确。我们研究了术中去甲肾上腺素与AKI之间的剂量-反应关系,及其与术中低血压的交互作用。我们分析了医学信息学手术室生命体征与事件数据库中的27 874例手术病例。主要暴露为术中去甲肾上腺素剂量,以去甲肾上腺素碱表示(μg kg-1 min-1)。主要结局为术后7天内发生的AKI。采用限制性立方样条和张量积广义相加模型评估最大剂量、时间加权强度、持续时间和曲线下面积(AUC),并使用有向无环图推导的调整集进行多变量混合效应逻辑回归。1232例患者(4.4%)接受了去甲肾上腺素,4448例(16.0%)发生AKI。限制性立方样条分析显示,单位速率指标具有显著非线性(最大剂量P=0.008;时间加权强度P=0.022),而时间整合指标呈线性(AUC P=0.10;持续时间P=0.50)。确定了最大去甲肾上腺素剂量的两个床旁可读锚点,分别为0.029和0.064 μg kg-1 min-1。剂量-持续时间交互(P=0.286)和剂量-低血压交互(P=0.298)不显著,支持相加效应。最大去甲肾上腺素剂量>0.029 μg kg-1 min-1仍与AKI独立相关(比值比[OR] 1.76;95%置信区间[CI] 1.41-2.20;P<0.001);对术中低血压进行调整后,该关联仅轻微减弱(5.1%;调整后OR 1.71;95% CI 1.36-2.15)。术中去甲肾上腺素暴露与术后AKI独立相关,单位速率指标呈非线性,时间整合指标呈线性,且在很大程度上独立于术中低血压。这两个锚点定义了一个两级警戒框架。
Kidney international IF 21.8 2026-10 PMID: 42486191
Thrombotic microangiopathy (TMA) is characterized by the classical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Complement inhibition with eculizumab is highly efficacious in TMA secondary to complement dysregulation. However, a growing number of eculizumab-nonresponsive TMAs are reported. Recently, a syndromic form of TMA due to recessive variants in RNA exosome components (EXOSC3 and EXOSC5) has been identified. The underlying pathogenesis remains unclear. We identified 34 children across Europe with pontocerebellar hypoplasia 1b (PCH1b) due to EXOSC3 rare variants and reviewed their clinical history for signs of TMA. To further examine the pathogenesis, a tamoxifen-inducible whole-body Exosc3 conditional knockout mouse model (Exosc3KO) was used. Thirteen (eight male, five female) cases of EXOSC3-TMA were identified. In the United Kingdom, the incidence of EXOSC3-TMA was 0.004/million/year. Three children received long-term eculizumab therapy: one child failed to respond and two relapsed on treatment. Exosc3KO demonstrated cell-cycle arrest and apoptosis resulting in death in a median of eight days, with sequelae noted in actively dividing cells in the bone marrow and large intestine. In this timeframe, no kidney pathology was identified. EXOSC3-TMA is a severe, early-onset, C5 inhibitor-resistant TMA. EXOSC3-TMA should be considered in eculizumab-resistant pediatric TMA, particularly in the context of neurodevelopmental disease.
中文摘要:血栓性微血管病(TMA)以微血管病性溶血性贫血、血小板减少和急性肾损伤的经典三联征为特征。依库珠单抗补体抑制对继发于补体失调的TMA高度有效。然而,越来越多对依库珠单抗无反应的TMA被报道。近期,已发现一种由RNA外切体组分(EXOSC3和EXOSC5)隐性变异导致的综合征型TMA。其潜在发病机制仍不清楚。我们识别了欧洲34例因EXOSC3罕见变异导致脑桥小脑发育不全1b型(PCH1b)的儿童,并回顾其临床病史以寻找TMA体征。为进一步探究发病机制,使用了他莫昔芬诱导的全身性Exosc3条件性敲除小鼠模型(Exosc3KO)。共识别出13例(8例男性,5例女性)EXOSC3-TMA病例。在英国,EXOSC3-TMA的发病率为0.004/百万/年。3名儿童接受了长期依库珠单抗治疗:1名儿童治疗无反应,2名在治疗中复发。Exosc3KO表现出细胞周期停滞和凋亡,导致中位8天内死亡,并在骨髓和大肠的活跃分裂细胞中观察到后遗效应。在此时间范围内,未发现肾脏病理改变。EXOSC3-TMA是一种严重的、早发、C5抑制剂耐药的TMA。在依库珠单抗耐药的儿童TMA中,尤其伴有神经发育疾病时,应考虑EXOSC3-TMA。
American journal of respiratory and critical care medicine IF 21.7 2026-10-01 PMID: 42275170
Empiric anti-pseudomonal coverage is an important part of treatment of sepsis, but there are limited data to guide antibiotic selection. The Antibiotic Choice on Renal Outcomes (ACORN) randomized trial found no difference in mortality when comparing cefepime and piperacillin-tazobactam, while an instrumental variable (IV) study found improved mortality with cefepime. To determine if white blood cell (WBC) count modifies the effect of antibiotic choice on mortality. We conducted post hoc subgroup analyses of the ACORN trial and the IV study comparing cefepime to piperacillin-tazobactam. We performed regression modeling of interaction between treatment group and WBC on 28-day mortality with adjustment for relevant covariates, with evaluation for heterogeneity of treatment effect through likelihood ratio testing. The main outcome was 28-day mortality in both cohorts. Secondary outcomes in the secondary analysis of the ACORN trial included highest stage of acute kidney injury on an ordinal scale, a composite outcome of major adverse kidney events, and incidence of coma or delirium within 14 days. There was a significant interaction between WBC and treatment group in predicting 28-day mortality in both the ACORN trial and the IV study (odds ratio [OR], 0.95 [95% CI, 0.92-0.98], P <.01 and OR, 0.95 [95% CI, 0.94-0.96], P <.01, respectively), with likelihood ratio testing revealing better model fit with inclusion of the interaction term (F = 8.17, P =<.01 and F = 42.9, P <.01, respectively). In the ACORN cohort, patients with a baseline WBC count of 16 or higher had significantly lower odds of mortality when treated with piperacillin-tazobactam compared to cefepime (OR, 0.51 [95% CI, 0.29-0.90]). WBC modified the effect of antibiotic choice on mortality in 2 large clinical studies. Further research is needed to confirm this effect in prospective studies and to determine if WBC count could be used for predictive enrichment in future trials of anti-pseudomonal antibiotics.
中文摘要:经验性抗假单胞菌覆盖是脓毒症治疗的重要组成部分,但指导抗生素选择的数据有限。抗生素选择对肾脏结局(ACORN)随机试验在比较头孢吡肟与哌拉西林-他唑巴坦时未发现死亡率差异,而一项工具变量(IV)研究则发现头孢吡肟可改善死亡率。旨在确定白细胞(WBC)计数是否改变抗生素选择对死亡率的影响。我们对ACORN试验和比较头孢吡肟与哌拉西林-他唑巴坦的IV研究进行了事后亚组分析。我们通过回归模型分析治疗组与WBC对28天死亡率的交互作用,并校正相关协变量,同时通过似然比检验评估治疗效应的异质性。两个队列的主要结局均为28天死亡率。ACORN试验二次分析的次要结局包括按有序尺度划分的急性肾损伤最高分期、主要不良肾脏事件的复合结局,以及14天内昏迷或谵妄的发生率。在ACORN试验和IV研究中,WBC与治疗组在预测28天死亡率方面均存在显著交互作用(分别为比值比[OR] 0.95 [95% CI, 0.92-0.98],P < .01;OR 0.95 [95% CI, 0.94-0.96],P < .01),似然比检验显示纳入交互项后模型拟合更佳(分别为F = 8.17,P =< .01;F = 42.9,P < .01)。在ACORN队列中,基线WBC计数为16或更高的患者接受哌拉西林-他唑巴坦治疗时,死亡比值显著低于接受头孢吡肟治疗者(OR 0.51 [95% CI, 0.29-0.90])。WBC在两项大型临床研究中改变了抗生素选择对死亡率的影响。需要进一步研究在前瞻性研究中证实这一效应,并确定WBC计数是否可用于未来抗假单胞菌抗生素试验的预测性富集。

基础研究 (4篇)

Redox biology IF 16.2 2026-10-01 PMID: 42826479
The epigenetic mechanisms driving the transition to ferroptosis in acute kidney injury (AKI) remain unclear. In this study, protein methyltransferase 5 (PRMT5) and its partner MEP50 were significantly upregulated in the renal tubules of AKI patients and murine models. Genetic silencing of PRMT5 via AAV-shRNA in vivo and siRNA in vitro improved renal function, attenuated mitochondrial damage, and suppressed ferroptotic tubular cell death. Mechanistically, PRMT5 promotes ACSL4 expression in a WDR5-dependent manner, facilitating tubular ferroptosis. Pharmacological inhibition of PRMT5 (GSK591) post-treatment or cloperastine hydrochloride prophylactic administration similarly improved renal function and limited ferroptotic cell death. These findings offer novel insights into the upstream epigenetic regulation of ACSL4-driven ferroptosis and suggest that PRMT5-ACSL4 axis might be a potential therapeutic target for AKI intervention.
中文摘要:驱动急性肾损伤(AKI)向铁死亡转变的表观遗传机制仍不清楚。在本研究中,蛋白甲基转移酶5(PRMT5)及其伙伴MEP50在AKI患者和小鼠模型的肾小管中显著上调。通过体内AAV-shRNA和体外siRNA对PRMT5进行基因沉默,可改善肾功能、减轻线粒体损伤并抑制铁死亡性肾小管细胞死亡。机制上,PRMT5以WDR5依赖的方式促进ACSL4表达,从而促进肾小管铁死亡。药理学抑制PRMT5(GSK591)的后处理或氯哌斯汀盐酸盐的预防性给药同样改善肾功能并限制铁死亡性细胞死亡。这些发现为ACSL4驱动的铁死亡的上游表观遗传调控提供了新见解,并提示PRMT5-ACSL4轴可能是AKI干预的潜在治疗靶点。
Biomarker research IF 14.6 2026-10-01 PMID: 42823774
Ischemia-reperfusion injury (IRI) contributes to the pathogenesis of major diseases, including acute kidney injury, stroke, and myocardial infarction. Multiple forms of cell death, including apoptosis, necroptosis, pyroptosis, autophagy, and ferroptosis, are key contributors to IRI. The interplay among these cell-death programs adds to the complexity of the IRI landscape. Cell-death patterns differ markedly between the ischemic and reperfusion phases and across organs, reflecting the spatiotemporal and organ-specific features of IRI. Given the complex molecular mechanisms underlying IRI, multi-target small-molecule drugs, combination regimens, and nanodelivery systems have been explored, although most remain at the preclinical stage. In this review, we summarize the major cell-death modalities involved in IRI, their interconnected molecular targets and signaling pathways, and their phase-specific and organ-specific regulation. We further discuss the coordinated roles of non-coding RNAs, metabolic reprogramming, and epigenetic alterations in regulating cell death, as well as their therapeutic potential. Finally, we propose therapeutic strategies aimed at modulating crosstalk among cell-death modalities, with potential implications for individualized IRI therapy.
中文摘要:缺血再灌注损伤(IRI)参与急性肾损伤、卒中和心肌梗死等重大疾病的发病过程。包括凋亡、坏死性凋亡、焦亡、自噬和铁死亡在内的多种细胞死亡形式是IRI的关键促成因素。这些细胞死亡程序之间的相互作用进一步增加了IRI病理格局的复杂性。细胞死亡模式在缺血期与再灌注期之间以及不同器官之间存在显著差异,反映了IRI的时空特征和器官特异性。鉴于IRI的复杂分子机制,多靶点小分子药物、联合方案和纳米递送系统已被探索,但大多数仍处于临床前阶段。在本综述中,我们总结了IRI涉及的主要细胞死亡方式、其相互关联的分子靶点和信号通路,以及这些细胞死亡方式的时相特异性和器官特异性调控。我们进一步讨论了非编码RNA、代谢重编程和表观遗传改变在调控细胞死亡中的协同作用及其治疗潜力。最后,我们提出旨在调节不同细胞死亡方式之间串扰的治疗策略,并探讨其对个体化IRI治疗的潜在意义。
Carbohydrate polymers IF 13.2 2026-10-01 PMID: 42586640
Circulating histones are critical inflammatory mediators that drive hyperinflammation and organ failure in critical illnesses such as sepsis, acute kidney injury, and acute respiratory distress syndrome. Their plasma levels are significantly correlated with disease severity and mortality in such patients. Although both DNA and sulfonic acid-containing macromolecules bind histones via electrostatic interactions, the primary challenge in integrating these antagonists into a unified anti-histone system lies in their mutual water solubility and similar negative charges. Herein, we fabricate novel chitosan/DNA-poly(sodium-4-styrenesulfonate) porous microspheres (C3D1-PSS) by employing a stepwise strategy involving phase inversion and subsequent in situ crosslinking polymerization. With a high-density, negatively charged histone capture network, the C3D1-PSS microspheres exhibit excellent hemocompatibility and achieve a notable histone adsorption ratio of 86.47% within 2 h and 95.52% within 4 h through synergistic electrostatic interactions mediated by phosphate and sulfonate groups in vitro. Furthermore, the C3D1-PSS microspheres significantly mitigate histone-induced thrombocytopenia, platelet activation, hemolysis, cytokine release, and endothelial cell death. In a histone-induced rabbit sepsis model, the C3D1-PSS microspheres efficiently alleviate histone-induced thrombocytopenia, tissue damage, hyperinflammation, and cell apoptosis. Collectively, this work presents a promising adsorbent for extracorporeal removal of histones and holds potential for managing histone-associated critical illnesses.
中文摘要:循环组蛋白是危重症(如脓毒症、急性肾损伤和急性呼吸窘迫综合征)中驱动过度炎症和器官衰竭的关键炎症介质。其血浆水平与这类患者的疾病严重程度和死亡率显著相关。尽管DNA和含磺酸基大分子均可通过静电相互作用结合组蛋白,但将这些拮抗剂整合为统一的抗组蛋白系统的主要挑战在于它们相互的水溶性和相似的负电荷。在此,我们通过采用相转化及随后原位交联聚合的分步策略,制备了新型壳聚糖/DNA-聚(4-苯乙烯磺酸钠)多孔微球(C3D1-PSS)。凭借高密度、带负电荷的组蛋白捕获网络,C3D1-PSS微球表现出优异的血液相容性,并在体外通过磷酸基和磺酸基介导的协同静电相互作用,在2小时内实现86.47%的显著组蛋白吸附率,4小时内达到95.52%。此外,C3D1-PSS微球显著减轻组蛋白诱导的血小板减少、血小板活化、溶血、细胞因子释放和内皮细胞死亡。在组蛋白诱导的兔脓毒症模型中,C3D1-PSS微球有效缓解组蛋白诱导的血小板减少、组织损伤、过度炎症和细胞凋亡。总之,这项工作提出了一种有前景的吸附剂,用于体外清除组蛋白,并具有管理组蛋白相关危重症的潜力。
Kidney international IF 21.8 2026-10 PMID: 42498057
Contrast-induced acute kidney injury (CIAKI) is a leading cause of hospital-acquired kidney dysfunction, yet its immune-mediated pathogenic mechanisms remain poorly defined. Neutrophil extracellular traps (NETs) have been implicated in acute kidney injury. However, whether contrast agents directly induce NETs formation and whether NETs drive tubular ferroptosis through IL-33 has not been investigated. A prospective cohort of 330 patients undergoing coronary angiography was enrolled, with serial measurement of circulating NETs markers (myeloperoxidase, neutrophil elastase) and IL-33 at pre-contrast, two- and 12-hour time points. A murine CIAKI model was established in wild-type, peptidyl arginine deaminase 4 (PAD4) -knockout, and IL-33-knockout mice, and single-cell transcriptomic profiling of CIAKI kidneys was performed. In vitro, the serine/threonine kinase IKKα- and β-catenin-overexpressing and knockdown HK-2 cells were stimulated with iodixanol-induced NETs to evaluate how NETs regulate ferroptosis through IL-33-mediated modulation of IKKα and β-catenin. CIAKI occurred in 12.1% (40/330) of patients. Circulating NETs markers and IL-33 were significantly elevated at two and 12 hours post-contrast in CIAKI compared with non-CIAKI patients. Single-cell transcriptomics identified neutrophils as the predominant source of IL-33 in CIAKI kidneys and revealed enrichment of NET formation and ferroptosis pathways. In vivo, PAD4 and IL-33 deficiency each significantly attenuated NETs and ferroptosis in CIAKI mice. Mechanistically, IL-33-enriched NETs suppressed IKKα expression, disrupted IKKα-β-catenin interaction, and impaired β-catenin nuclear translocation, thereby de-repressing long chain acyl CoA synthetase 4 transcription and amplifying ferroptotic injury. Restoration of IKKα stabilized β-catenin and attenuated NET-induced ferroptosis. Our study demonstrates that IL-33-enriched NETs promote renal tubular ferroptosis in CIAKI by suppressing IKKα and impairing β-catenin nuclear translocation. These findings identify the NETs-IL-33-IKKα-β-catenin pathway as a novel and therapeutically actionable mechanism underlying CIAKI, providing potential targets for its diagnosis and treatment.
中文摘要:造影剂诱导的急性肾损伤(CIAKI)是医院获得性肾功能不全的主要原因,但其免疫介导的致病机制仍不明确。中性粒细胞胞外诱捕网(NETs)已被认为与急性肾损伤有关。然而,造影剂是否直接诱导NETs形成以及NETs是否通过IL-33驱动肾小管铁死亡尚未被研究。研究纳入330例接受冠状动脉造影的前瞻性队列患者,在造影前、造影后2小时和12小时连续检测循环NETs标志物(髓过氧化物酶、中性粒细胞弹性蛋白酶)和IL-33。在野生型、肽基精氨酸脱氨酶4(PAD4)敲除和IL-33敲除小鼠中建立CIAKI小鼠模型,并对CIAKI肾脏进行单细胞转录组分析。体外实验中,用碘克沙醇诱导的NETs刺激过表达和敲低丝氨酸/苏氨酸激酶IKKα与β-catenin的HK-2细胞,以评估NETs如何通过IL-33介导的IKKα和β-catenin调控来调节铁死亡。12.1%(40/330)患者发生CIAKI。与未发生CIAKI的患者相比,CIAKI患者造影后2小时和12小时循环NETs标志物和IL-33显著升高。单细胞转录组学鉴定中性粒细胞是CIAKI肾脏中IL-33的主要来源,并揭示NET形成和铁死亡通路的富集。体内实验中,PAD4和IL-33缺陷均显著减轻CIAKI小鼠的NETs和铁死亡。机制上,富含IL-33的NETs抑制IKKα表达,破坏IKKα-β-catenin相互作用,并损害β-catenin核转位,从而解除长链脂酰辅酶A合成酶4转录的抑制并放大铁死亡损伤。恢复IKKα可稳定β-catenin并减轻NET诱导的铁死亡。我们的研究表明,富含IL-33的NETs通过抑制IKKα和损害β-catenin核转位促进CIAKI中的肾小管铁死亡。这些发现确定NETs-IL-33-IKKα-β-catenin通路是CIAKI背后一种新的且具有治疗可操作性的机制,为其诊断和治疗提供了潜在靶点。

3肾移植 (4篇)

临床研究 (4篇)

Annals of internal medicine IF 17.2 2026-10-06 PMID: 42832810
GIM/FP/GP: [Formula: see text] Nephrology: [Formula: see text].
中文摘要:GIM/FP/GP:[公式:见正文] 肾脏病学:[公式:见正文]。
Kidney international IF 21.8 2026-10 PMID: 42508609
Despite the prevalent notion that early acute T cell-mediated rejection (TCMR) in kidney transplant patients is clinically benign, how it responds to treatment and whether treatment responses impact long-term graft survival remain unclear and poorly characterized. To comprehensively address this issue, we conducted an observational cohort study of all adult patients who underwent kidney transplantation between January 2013 and December 2019 across six centers in the United States and Europe. We evaluated the incidence of TCMR in the first post-transplant year, assessed clinical and histological responses to treatment, and examined their association with long-term graft outcomes. Among 5,762 patients undergoing 9,780 biopsies, 790 (13.6%) developed TCMR. Despite treatment, 36% of patients demonstrated clinical deterioration and 32% had persistent TCMR on follow-up biopsy, indicating frequent treatment resistance. Clinical and histologic responses were frequently discordant. While only 51% of patients with clinical improvement had no rejection, 37% with clinical deterioration also showed no rejection. TCMR was significantly associated with worse graft survival (death-censored graft loss hazard ratio 2.84, 95% confidence interval 2.38-3.3). Importantly, persistent TCMR conferred a substantially higher risk of graft loss compared with responsive TCMR (3.21, 2.19-4.71) independent of clinical response and other confounders. This association was consistent across subgroups and supported by time-dependent and landmark analyses. Increasing tubulointerstitial inflammation (Banff Δ 't+i' scores) demonstrated a graded association with adverse outcomes, and trajectory analyses showed a stepwise increase in graft loss with persistent or recurrent inflammation. TCMR is common, frequently treatment-resistant, and persistent TCMR is strongly associated with inferior long-term graft survival. Clinical improvement often failed to reflect histologic response. These findings challenge the notion that TCMR is clinically benign and identify persistent inflammation as a key driver of graft loss, underscoring the need for response guided monitoring and more effective targeted therapies.
中文摘要:尽管普遍认为肾移植患者中的早期急性T细胞介导的排斥反应(TCMR)在临床上呈良性,但其对治疗的反应如何,以及治疗反应是否影响长期移植物生存,仍不清楚且缺乏系统描述。为全面解决该问题,我们开展了一项观察性队列研究,纳入2013年1月至2019年12月期间在美国和欧洲六个中心接受肾移植的所有成年患者。我们评估了移植后第一年TCMR的发生率,评估了对治疗的临床和组织学反应,并考察了它们与长期移植物结局的关联。在5,762例接受9,780次活检的患者中,790例(13.6%)发生TCMR。尽管接受了治疗,36%的患者出现临床恶化,32%在随访活检中表现为持续性TCMR,提示治疗抵抗常见。临床反应和组织学反应常不一致。临床改善的患者中仅51%无排斥反应,而临床恶化的患者中37%也无排斥反应。TCMR与更差的移植物生存显著相关(死亡删失移植物丢失风险比2.84,95%置信区间2.38-3.3)。重要的是,与有反应的TCMR相比,持续性TCMR带来显著更高的移植物丢失风险(3.21,2.19-4.71),且独立于临床反应和其他混杂因素。该关联在各亚组中一致,并得到时间依赖分析和landmark分析的支持。肾小管间质炎症增加(Banff Δ「t+i」评分)与不良结局呈分级关联,轨迹分析显示,随着炎症持续或复发,移植物丢失呈逐步增加。TCMR常见,常对治疗抵抗,持续性TCMR与较差的长期移植物生存密切相关。临床改善往往不能反映组织学反应。这些发现挑战了TCMR临床上呈良性的观念,并确定持续性炎症是移植物丢失的关键驱动因素,强调需要以反应为导向的监测和更有效的靶向治疗。
Blood IF 23.9 2026-10-01 PMID: 42485768
Complement-mediated thrombotic microangiopathy can be difficult to recognize when it presents in the setting of an apparent clinical trigger, such as pregnancy, severe hypertension, or kidney transplantation. These conditions can each cause endothelial injury directly but may also unmask complement dysregulation in susceptible individuals. In these situations, the critical question is not whether a trigger exists but whether it fully explains the syndrome and whether urgent complement blockade is warranted to prevent irreversible kidney injury. In this How I Treat article, we use 3 real-world cases to illustrate how we approach this decision in practice. We emphasize the bedside features that most influence our threshold to treat, including the pattern and severity of kidney injury, tempo of disease progression, and lack of improvement with supportive or trigger-directed care. We also address the interpretation of complement genetic findings, pregnancy- and transplant-specific risk stratification, and the individualization of treatment duration. Functional assays can support mechanistic assessment in selected cases but remain an adjunct to diagnosis and should not drive management decisions.
中文摘要:补体介导的血栓性微血管病在表现为明显临床诱因(如妊娠、严重高血压或肾移植)时可能难以识别。这些情况均可直接导致内皮损伤,但也可能在易感个体中揭示补体调节异常。在这些情况下,关键问题不是是否存在诱因,而是该诱因能否完全解释此综合征,以及是否需要紧急补体阻断以防止不可逆的肾损伤。在这篇「How I Treat」文章中,我们使用3个真实世界病例来说明我们在实践中如何做出这一决策。我们强调最影响我们治疗阈值的床旁特征,包括肾损伤的模式和严重程度、疾病进展的速度,以及对支持治疗或针对诱因的治疗缺乏改善。我们还讨论补体遗传学发现的解读、妊娠和移植特异性的风险分层,以及治疗持续时间的个体化。功能测定可在部分病例中支持机制评估,但仍只是诊断的辅助手段,不应驱动管理决策。
Annals of the rheumatic diseases IF 24.0 2026-10 PMID: 42431783
This study aimed to develop a set of quality indicators (QIs) based on the 2025 European Alliance of Associations for Rheumatology (EULAR) recommendations for systemic lupus erythematosus with kidney involvement and explore their association with disease outcomes. A modified Research and Development and University of California, Los Angeles appropriateness method was used. In 2 voting rounds, 23 experts rated candidate QIs for validity and feasibility. Median ratings and agreement were calculated, leading to a core QI set. Adherence to recommended care from healthcare providers was assessed at both QI and patient levels in a single tertiary centre contemporary lupus nephritis (LN) cohort (n = 130). High adherence was defined as ≥80%. Associations between adherence to QIs, damage accrual, and renal flares were explored. A total of 17 QIs were developed across 4 domains: diagnosis, treatment, monitoring, and pregnancy. High adherence was observed for kidney biopsy, hydroxychloroquine use, maintenance immunosuppression, therapy switching in persistent or relapsing disease, renin-angiotensin system inhibitor use, remission before kidney transplantation, and pregnancy-related QIs. Combination immunosuppressive therapy as initial treatment had low adherence (10.7%), reflecting practice patterns preceding publication of the recommendations. High per-patient adherence was associated with lower odds of damage accrual (increase in Systemic Lupus International Collaborating Clinic Damage Index; odds ratio: 0.29, 95% CI: 0.13-0.62) and fewer renal flares, although the latter association was not statistically significant. These QIs may serve as a structured framework for implementing the 2025 EULAR recommendations for LN. Higher adherence was associated with reduced damage accrual in a tertiary centre cohort, but results need validation in diverse clinical settings.
中文摘要:本研究旨在基于2025年欧洲抗风湿病联盟(EULAR)关于伴肾脏受累的系统性红斑狼疮的建议,制定一套质量指标(QIs),并探讨其与疾病结局的关联。研究采用改良的RAND/加州大学洛杉矶分校(UCLA)适宜性方法。在两轮投票中,23名专家对候选质量指标的有效性和可行性进行评分。计算中位评分和一致性,形成核心质量指标集。在单中心三级医疗中心当代狼疮肾炎(LN)队列(n=130)中,从质量指标层面和患者层面评估医疗服务提供者对推荐诊疗的依从性。高依从性定义为≥80%。探讨质量指标依从性与损伤累积及肾脏复发之间的关联。共制定17项质量指标,涵盖4个领域:诊断、治疗、监测和妊娠。肾脏活检、羟氯喹使用、维持性免疫抑制、持续或复发性疾病中的治疗转换、肾素-血管紧张素系统抑制剂使用、肾移植前缓解以及妊娠相关质量指标均观察到高依从性。作为初始治疗的联合免疫抑制治疗依从性较低(10.7%),反映了该建议发布前的实践模式。较高的每例患者依从性与较低的损伤累积风险相关(系统性红斑狼疮国际协作组损伤指数升高;比值比:0.29,95% CI:0.13-0.62),并且与较少的肾脏复发相关,但后者的关联无统计学意义。这些质量指标可作为实施2025年EULAR关于LN建议的结构化框架。在三级医疗中心队列中,较高的依从性与损伤累积减少相关,但结果需要在不同临床环境中验证。

4糖尿病肾病 (2篇)

临床研究 (2篇)

JAMA network open IF 11.7 2026-10-01 PMID: 42826018
The risk of diabetic microvascular complications is well established among smokers with type 2 diabetes. However, whether and to what extent this excess risk declines according to smoking cessation duration remains unclear. To investigate the association between smoking cessation duration and the risk of incident diabetic microvascular complications in patients with diabetes. This nationwide, population-based cohort study included participants first diagnosed with type 2 diabetes in Korea between 2003 and 2013 and whose smoking status was assessed at least 4 times across repeated health checkups, with a final checkup during 2009 to 2013. Data were analyzed from November 10, 2025, to April 16, 2026. Smoking status and cessation duration. Quitters were defined as participants who reported current smoking at their initial health checkup and reported smoking cessation at all subsequent checkups without relapse. Continuous smokers were defined as participants who consistently reported current smoking at every health checkup. Among quitters, smoking cessation duration was categorized as less than 2, 2 to 3, 4 to 5, 6 to 7, and 8 or more years. Outcomes of interest were incident diabetic microvascular complications, including diabetic nephropathy, retinopathy, and neuropathy, identified using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnostic codes. Cox proportional hazards models were used to estimate unadjusted and adjusted hazard ratios (aHRs) and 95% CIs. A total of 209 698 adults (mean [SD] age, 57.2 [10.3] years; 127 823 [61.0%] female) were included in the analyses. Compared with continuous smokers, cessation for 8 or more years was associated with a lower risk of all microvascular complications (aHR, 0.81; 95% CI, 0.70-0.95), diabetic nephropathy (aHR, 0.79; 95% CI, 0.64-0.94), diabetic retinopathy (aHR, 0.59; 95% CI, 0.36-0.97), and diabetic neuropathy (aHR, 0.80; 95% CI, 0.66-0.98). Smoking cessation for 6 to 7 years was associated with lower risk of diabetic neuropathy (aHR, 0.76; 95% CI, 0.64-0.89). In subgroup analyses by sex, these associations were significant only among male participants (eg, all microvascular complications: aHR, 0.82; 95% CI, 0.70-0.95). In this retrospective cohort study of patients with diabetes, smoking cessation for 8 or more years was associated with a lower risk of all diabetic microvascular complications, diabetic nephropathy, retinopathy, and neuropathy compared with continuous smoking. These associations were observed mainly among male participants, underscoring the potential importance of sustained long-term smoking cessation for microvascular risk reduction.
中文摘要:在2型糖尿病吸烟者中,糖尿病微血管并发症的风险已被充分确立。然而,这一超额风险是否以及随戒烟持续时间延长而下降的程度仍不清楚。为探讨糖尿病患者戒烟持续时间与新发糖尿病微血管并发症风险之间的关联。这项全国性、基于人群的队列研究纳入2003年至2013年间在韩国首次诊断为2型糖尿病的参与者,这些参与者在多次重复健康体检中至少4次评估了吸烟状态,且最后一次体检在2009年至2013年期间。数据分析时间为2025年11月10日至2026年4月16日。暴露为吸烟状态和戒烟持续时间。戒烟者定义为在初次健康体检时报告当前吸烟,并在所有后续体检中报告戒烟且未复吸的参与者。持续吸烟者定义为在每次健康体检中均持续报告当前吸烟的参与者。在戒烟者中,戒烟持续时间分为不足2年、2至3年、4至5年、6至7年和8年及以上。关注结局为新发糖尿病微血管并发症,包括糖尿病肾病、视网膜病变和神经病变,通过国际疾病分类第十次修订版(ICD-10)诊断编码识别。采用Cox比例风险模型估计未调整和调整后的风险比(aHR)及95%CI。共纳入209 698名成人(平均[SD]年龄57.2[10.3]岁;127 823名[61.0%]女性)进行分析。与持续吸烟者相比,戒烟8年及以上与所有微血管并发症风险降低相关(aHR,0.81;95%CI,0.70-0.95)、糖尿病肾病(aHR,0.79;95%CI,0.64-0.94)、糖尿病视网膜病变(aHR,0.59;95%CI,0.36-0.97)和糖尿病神经病变(aHR,0.80;95%CI,0.66-0.98)。戒烟6至7年与糖尿病神经病变风险降低相关(aHR,0.76;95%CI,0.64-0.89)。按性别进行的亚组分析中,这些关联仅在男性参与者中显著(例如,所有微血管并发症:aHR,0.82;95%CI,0.70-0.95)。在这项糖尿病患者回顾性队列研究中,与持续吸烟相比,戒烟8年及以上与所有糖尿病微血管并发症、糖尿病肾病、视网膜病变和神经病变风险降低相关。这些关联主要在男性参与者中观察到,强调了长期持续戒烟对降低微血管风险的可能重要性。
Diabetes care IF 22.6 2026-10-01 PMID: 42507670
To quantify the excess risk of any fractures, major osteoporotic fractures (MOF), and hip fractures in type 1 diabetes (T1D) by age, stages of diabetic kidney disease (DKD), and sex and to evaluate risk factors for fractures. The study included 5,035 individuals from the Finnish Diabetic Nephropathy Study (FinnDiane) and 12,286 control individuals without diabetes. We assessed the standardized incidence ratios (SIRs) for fractures in individuals with T1D compared with control individuals. Cox regression analyses were conducted in individuals with T1D to identify potential factors associated with fractures. SIR for any fracture was 2.15 (95% CI 2.06-2.25), 2.60 (2.41-2.79) for MOF, and 5.24 (4.55-6.02) for hip fracture. SIR of hip fracture was the highest in those aged 40-49 years, 8.13 (5.75-11.2). All age-groups after 10-19 years had excess fracture risk. The SIR of any fracture increased with the DKD stages; 2.54 (2.36-2.72) in individuals without albuminuria, 3.47 (3.02-3.98) in those with moderate albuminuria, 3.73 (3.27-4.25) in those with severe albuminuria, and 5.08 (4.16-6.16) in those with kidney failure. SIRs for MOF were 2.62 (2.34-2.93) in those without albuminuria, 3.84 (3.10-4.71) in those with moderate albuminuria, 4.53 (3.72-5.48) in those with severe albuminuria, and 5.85 (4.38-7.68) in those with kidney failure. Hypoglycemic coma episodes (hazard ratio 1.04 [1.01-1.07]) and HbA1c (1.11 [1.06-1.15]) were associated with risk of any fracture, and episodes of diabetic ketoacidosis were associated with risk of MOF (1.18 [1.11-1.25]) in T1D. Findings suggest that fracture risk assessment may need to be considered earlier than currently recommended, especially among individuals with DKD.
中文摘要:旨在量化1型糖尿病(T1D)患者中任何骨折、主要骨质疏松性骨折(MOF)和髋部骨折的额外风险,并按年龄、糖尿病肾病(DKD)分期和性别分层,同时评估骨折的危险因素。本研究纳入芬兰糖尿病肾病研究(FinnDiane)中的5,035例个体和12,286例无糖尿病对照个体。我们评估了T1D个体与对照个体相比骨折的标化发病比(SIR)。在T1D个体中进行Cox回归分析,以识别与骨折相关的潜在因素。任何骨折的SIR为2.15(95% CI 2.06-2.25),MOF为2.60(2.41-2.79),髋部骨折为5.24(4.55-6.02)。髋部骨折的SIR在40-49岁年龄组最高,为8.13(5.75-11.2)。10-19岁之后的各年龄组均有骨折风险增加。任何骨折的SIR随DKD分期增加而升高:无白蛋白尿个体为2.54(2.36-2.72),中度白蛋白尿者为3.47(3.02-3.98),重度白蛋白尿者为3.73(3.27-4.25),肾衰竭者为5.08(4.16-6.16)。MOF的SIR在无白蛋白尿者为2.62(2.34-2.93),中度白蛋白尿者为3.84(3.10-4.71),重度白蛋白尿者为4.53(3.72-5.48),肾衰竭者为5.85(4.38-7.68)。低血糖昏迷发作(风险比1.04 [1.01-1.07])和HbA1c(1.11 [1.06-1.15])与任何骨折风险相关,而糖尿病酮症酸中毒发作与MOF风险相关(1.18 [1.11-1.25])在T1D中。研究结果提示,骨折风险评估可能需要比目前推荐更早考虑,尤其是在DKD个体中。

5遗传性肾病/囊性 (2篇)

临床研究 (2篇)

Kidney international IF 21.8 2026-10 PMID: 42760021
This commentary discusses the Lanreotide In Polycystic kidney disease Study (LIPS) that is published in this issue of Kidney International. It represents the last randomized evaluation of somatostatin analogues in patients with autosomal dominant polycystic kidney disease. Lanreotide did not demonstrate a beneficial effect on the primary outcome, measured glomerular filtration rate decline, but did suggest an effect on creatinine-estimated glomerular filtration rate slope. The discrepancy between both outcomes highlights important challenges in the interpretation of kidney function end points and statistical modeling. All in all, the findings of the LIPS trial support the current Kidney Disease: Improving Global Outcomes recommendation not to prescribe somatostatin analogues solely to preserve kidney function in autosomal dominant polycystic kidney disease.
中文摘要:本评论讨论了发表于本期《Kidney International》的兰瑞肽治疗多囊肾病研究(LIPS)。该研究是对生长抑素类似物在常染色体显性多囊肾病患者中进行的最后一项随机评估。兰瑞肽未显示对主要结局即实测肾小球滤过率下降具有有益作用,但提示对肌酐估算的肾小球滤过率斜率有影响。两项结局之间的差异凸显了肾功能终点指标解读及统计建模方面的重要挑战。总之,LIPS试验的结果支持当前「改善全球肾脏病预后组织」的建议,即不应仅为保留常染色体显性多囊肾病患者的肾功能而处方生长抑素类似物。
Kidney international IF 21.8 2026-10 PMID: 42320793
Somatostatin analogues reduce liver and kidney cyst volume in autosomal dominant polycystic kidney disease (ADPKD), but randomized trials have not demonstrated a consistent benefit on kidney function decline. We tested whether the analogue lanreotide slows glomerular filtration rate (GFR) decline over three years in adults with ADPKD stages 2/3. In this randomized, double-blind, placebo-controlled trial, we enrolled adults with ADPKD and measured GFR (mGFR) 30-89 ml/min/1.73 m2. Patients were randomized to receive monthly injections of lanreotide 120 mg or 0.9% sodium chloride placebo for three years. The primary endpoint was mGFR slope (iohexol clearance) assessed at baseline, weeks 72 and 144 and analyzed with a linear mixed-effects model (LMM). Secondary endpoints included annual estimated GFR decline (creatinine-based, assessed at 11 scheduled visits), kidney events, quality of life, and safety. Due to slow enrollment, recruitment stopped after 144 of 180 planned participants. All randomized participants were included in the analysis (intention-to-treat). The primary endpoint was not met: the model-derived annualized between-arm difference in mGFR trajectory was -0.3 ml/min/1.73 m2 per year (95% confidence interval -3.4 to 2.8). The time × lanreotide coefficient from the pre-specified creatinine-eGFR LMM was significant +1.2 ml/min/1.73 m2 per year (0.27 to 2.15); however, this signal was not replicated by cystatin C-eGFR nor urinary creatinine clearance, consistent with a non-GFR effect on creatinine physiology. Rates of kidney events and quality-of-life scores were similar between arms. Gastrointestinal adverse events were more frequent with lanreotide. Hypoglycemia occurred in 11.1% of lanreotide-treated versus 1.4% of placebo-treated participants. Lanreotide did not slow mGFR decline in adults with stage 2/3 ADPKD. The creatinine-eGFR signal is exploratory, not supported by muscle-mass-independent markers, and should be interpreted in the context of a negative primary endpoint. An unexpected hypoglycemia signal warrants proactive monitoring when considering lanreotide in this population. Registered at ClinicalTrials.gov with study number NCT02127437.
中文摘要:生长抑素类似物可减少常染色体显性多囊肾病(ADPKD)患者的肝囊肿和肾囊肿体积,但随机试验尚未显示其对肾功能下降具有一致的获益。我们检验了类似物兰瑞肽是否能减缓2/3期ADPKD成人患者三年内的肾小球滤过率(GFR)下降。在这项随机、双盲、安慰剂对照试验中,我们纳入了ADPKD成人患者,并测量GFR(mGFR)为30-89 ml/min/1.73 m2。患者被随机分配接受每月注射兰瑞肽120 mg或0.9%氯化钠安慰剂,持续三年。主要终点为mGFR斜率(碘海醇清除率),在基线、第72周和第144周评估,并采用线性混合效应模型(LMM)分析。次要终点包括年度估算GFR下降(基于肌酐,在11次计划访视中评估)、肾脏事件、生活质量和安全性。由于入组缓慢,招募在计划的180名参与者中的144名后停止。所有随机化参与者均纳入分析(意向性治疗)。主要终点未达到:模型推导的组间mGFR轨迹年化差异为-0.3 ml/min/1.73 m2/年(95%置信区间 -3.4至2.8)。预先设定的肌酐-eGFR LMM中的时间×兰瑞肽系数显著为+1.2 ml/min/1.73 m2/年(0.27至2.15);然而,该信号未能在胱抑素C-eGFR或尿肌酐清除率中重复,这与对肌酐生理学的非GFR效应一致。两组肾脏事件发生率和生活质量评分相似。兰瑞肽组的胃肠道不良事件更频繁。低血糖发生在11.1%的兰瑞肽治疗者中,而安慰剂治疗者为1.4%。兰瑞肽未减缓2/3期ADPKD成人患者的mGFR下降。肌酐-eGFR信号为探索性,未得到不依赖肌肉量的标志物支持,应在主要终点阴性的背景下解读。一个意外的低血糖信号提示,在该人群中考虑使用兰瑞肽时需要主动监测。已在ClinicalTrials.gov注册,研究编号为NCT02127437。

6肾小球疾病 (2篇)

临床研究 (1篇)

Intensive care medicine IF 22.0 2026-10 PMID: 42455344
Antiseizure medications (ASMs) are commonly used in the intensive care unit (ICU) and often exhibit pharmacokinetics that differ substantially from those in healthy volunteers or in the outpatient setting. Organ dysfunction, polypharmacy, exogenous devices, and greater severity of illness all influence ASM pharmacokinetics, dosing decisions, and monitoring parameters. It is essential for critical care clinicians to familiarize themselves with the pharmacokinetics, dosing considerations, effects of exogenous devices, and therapeutic drug monitoring (TDM)-all covered in this narrative review-to incorporate in their approach to ASMs in the critical care setting. We identified relevant literature from MEDLINE from inception to March 2026 related to ASMs in the ICU. Data on pharmacokinetics, dosing in the ICU, the effect of renal replacement therapy, extracorporeal membrane oxygenation (ECMO), and plasmapheresis (PLEX) on ASM exposure, and the role of TDM in the ICU were collected and summarized. Considerations for 15 ASMs (brivaracetam, cannabidiol, carbamazepine, cenobamate, clobazam, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, phenobarbital, phenytoin, topiramate, valproate, and zonisamide) were included in the review. Dosing considerations for TDM, including indications and target reference ranges, and specific settings such as organ dysfunction, illness severity, renal replacement therapy, ECMO, and PLEX are discussed. The use of ASMs in the ICU require a distinct approach from outpatient settings. Severity of illness, organ dysfunction and replacement devices, and frequent drug-drug interactions warrant tailored agent selection, dosing, and monitoring.
中文摘要:抗癫痫发作药物(ASMs)在重症监护病房(ICU)中常用,其药代动力学常与健康志愿者或门诊环境存在显著差异。器官功能障碍、多重用药、体外装置以及疾病严重程度更高,均会影响ASM的药代动力学、给药决策和监测参数。重症监护临床医生必须熟悉药代动力学、给药考虑、体外装置的影响以及治疗药物监测(TDM)——本叙述性综述均涵盖这些内容——并将其纳入重症监护环境中使用ASM的思路。我们检索了MEDLINE中自建库至2026年3月与ICU中ASM相关的文献。收集并总结了药代动力学、ICU中的给药、肾脏替代治疗、体外膜氧合(ECMO)和血浆置换(PLEX)对ASM暴露的影响,以及TDM在ICU中的作用等数据。本综述纳入了15种ASM(布瓦西坦、大麻二酚、卡马西平、塞诺氨酯、氯巴占、拉考沙胺、拉莫三嗪、左乙拉西坦、奥卡西平、吡仑帕奈、苯巴比妥、苯妥英、托吡酯、丙戊酸和唑尼沙胺)的考虑事项。讨论了TDM的给药考虑,包括适应证和目标参考范围,以及器官功能障碍、疾病严重程度、肾脏替代治疗、ECMO和PLEX等特定情况。ICU中ASM的使用需要采取与门诊环境不同的方法。疾病严重程度、器官功能障碍和替代装置,以及频繁的药物相互作用,均要求个体化选择药物、给药和监测。

基础研究 (1篇)

Journal of advanced research IF 17.1 2026-10 PMID: 41534548
Minimal Change Disease (MCD) represents a prevalent pathological cause of nephrotic syndrome. While podocyte injury is recognized as the direct cause of proteinuria in MCD, aberrant T-cell activation is a key driver of this podocyte damage. However, the absence of T-cell infiltration in renal biopsies and ineffectiveness of immunosuppressive therapy in a subset of patients suggest the existence of undiscovered key mechanisms underlying MCD immunopathogenesis. This study investigates the role of podocyte-derived exosomes (Pdo-Exos) in T cell activation via antigen presentation in MCD. Using an in vitro co-culture system, a puromycin aminonucleoside (PAN)-induced MCD mouse model, and clinical samples, we evaluated the immunostimulatory capacity of Pdo-Exos, focusing on antigen presentation via MHC-I and Rab27a-regulated exosome secretion. Pdo-Exos activated CD8+ T cells through MHC-I without promoting proliferation, indicating a role for dendritic cell-mediated cross-presentation. In OT-I mice, OVA-loaded Pdo-Exos exacerbated proteinuria and activated both tissue-resident and lymphoid T cells. MCD patients exhibited increased circulating activated T cells, and their podocyte exosomes showed significantly elevated MHC-I and co-stimulatory molecule CD80. Rab27a-dependent exosome secretion exacerbated disease severity, while inhibition of Rab27a mitigated proteinuria and inflammation. Podocyte-derived exosomes mediate CD8+ T cell activation by acting as antigen-presenting vesicles, with DCs facilitating T cell expansion. Rab27a-dependent exosome secretion contributes to MCD progression, highlighting a novel therapeutic strategy.
中文摘要:微小病变肾病(MCD)是肾病综合征常见的病理病因。虽然足细胞损伤被认为是MCD中蛋白尿的直接原因,但异常的T细胞活化是导致这种足细胞损伤的关键驱动因素。然而,肾活检中缺乏T细胞浸润以及部分患者免疫抑制治疗无效,提示MCD免疫发病机制中存在尚未发现的关键机制。本研究探讨足细胞来源外泌体(Pdo-Exos)在MCD中通过抗原呈递参与T细胞活化的作用。我们利用体外共培养系统、嘌呤霉素氨基核苷(PAN)诱导的MCD小鼠模型以及临床样本,评估Pdo-Exos的免疫刺激能力,重点关注通过MHC-I进行的抗原呈递以及Rab27a调控的外泌体分泌。Pdo-Exos通过MHC-I活化CD8+ T细胞而不促进其增殖,提示树突状细胞介导的交叉呈递发挥作用。在OT-I小鼠中,负载OVA的Pdo-Exos加重蛋白尿,并活化组织驻留和淋巴样T细胞。MCD患者外周血活化的T细胞增多,其足细胞外泌体的MHC-I和共刺激分子CD80显著升高。Rab27a依赖性外泌体分泌加重疾病严重程度,而抑制Rab27a则减轻蛋白尿和炎症。足细胞来源外泌体作为抗原呈递囊泡介导CD8+ T细胞活化,树突状细胞促进T细胞扩增。Rab27a依赖性外泌体分泌促进MCD进展,提示一种新的治疗策略。

7高血压/电解质/酸碱 (1篇)

临床研究 (1篇)

Pharmacological research IF 12.2 2026-10 PMID: 42669336
Kidney transplantation (KT) remains the optimal treatment for kidney failure, improving survival and quality of life. However, long-term graft outcomes have plateaued, largely due to transplant CKD and cardiovascular disease; agents such as mineralocorticoid receptor antagonists (MRAs) may help mitigate these risks. Mineralocorticoid receptor (MR) overactivation contributes to oxidative stress, inflammation, and fibrosis in both the heart and kidneys, suggesting a potential role for mineralocorticoid receptor antagonists (MRAs) in improving long-term patient and graft outcomes. Although evidence in KT is limited, MR blockade may offer clinical benefits by targeting aldosterone-mediated pathways. Proteinuria promotes sodium reabsorption in the aldosterone-sensitive distal nephron via epithelial sodium channels (ENaC), contributing to hypertension and volume overload. MRAs have been shown to reduce albuminuria and blood pressure in patients with diabetic nephropathy, even on background renin-angiotensin-aldosterone system (RAAS) blockade. The use of MRAs post-KT should be individualized, considering patient comorbidities and concomitant immunosuppressive therapy. While MRAs may provide cardiovascular and antiproteinuric benefits, the risk of hyperkalemia-though reduced with non-steroidal MRAs-must be carefully managed.
中文摘要:肾移植(KT)仍是肾衰竭的最佳治疗方法,可改善生存率和生活质量。然而,长期移植物结局已趋于平台期,主要原因是移植后慢性肾脏病和心血管疾病;盐皮质激素受体拮抗剂(MRAs)等药物可能有助于减轻这些风险。盐皮质激素受体(MR)过度激活会促进心脏和肾脏中的氧化应激、炎症和纤维化,提示盐皮质激素受体拮抗剂(MRAs)可能有助于改善患者和移植物的长期结局。尽管在肾移植中的证据有限,但MR阻断可能通过靶向醛固酮介导的通路提供临床获益。蛋白尿通过上皮钠通道(ENaC)促进醛固酮敏感性远端肾单位中的钠重吸收,从而导致高血压和容量超负荷。在糖尿病肾病患者中,即使已接受背景肾素-血管紧张素-醛固酮系统(RAAS)阻断治疗,MRAs也已被证明可减少白蛋白尿和降低血压。肾移植后使用MRAs应个体化,需考虑患者合并症和同时使用的免疫抑制治疗。虽然MRAs可能提供心血管和抗蛋白尿获益,但高钾血症风险——尽管非甾体类MRAs可降低该风险——必须谨慎管理。

8基础/转化研究 (1篇)

基础研究 (1篇)

Kidney international IF 21.8 2026-10 PMID: 42492857
Chronic kidney disease has traditionally been conceptualized through a glomerular lens. However, extensive clinicopathologic data show that tubulointerstitial fibrosis and tubular atrophy are stronger predictors of long-term renal outcome than glomerular lesions, even in conditions historically labeled as glomerular. Recent single-cell and spatial multiomic studies further reveal that tubular epithelial cells in chronically diseased kidneys occupy distinct, tightly regulated states that orchestrate inflammation, metabolic reprogramming, and extracellular matrix remodeling within spatially organized fibrotic niches. In this Review, we propose a whole-nephron framework for chronic kidney disease progression. We revisit the historical dominance of the glomerular paradigm and summarize evidence that tubulointerstitial damage is a principal structural determinant of renal function. We then outline how hemodynamic-hypoxic, metabolic-toxic, and immune-inflammatory insults converge on tubular epithelial cells and the peritubular microvasculature to trigger maladaptive epithelial programs-including cell cycle arrest and senescence, metabolic reprogramming and mitochondrial dysfunction, and sustained inflammatory and profibrotic activation. We describe the tubulointerstitium as a dynamic epithelial-stromal-vascular-immune network in which self-reinforcing fibrotic niches emerge. Finally, we discuss therapeutic and biomarker implications of an integrated, nephron-centric perspective, arguing that disease-modifying strategies will require targeting specific maladaptive tubular programs and their crosstalk with the interstitium, alongside established glomerular-directed therapies.
中文摘要:慢性肾脏病传统上是通过肾小球的视角来概念化的。然而,大量临床病理数据显示,即使在历史上被标记为肾小球疾病的状况中,肾小管间质纤维化和肾小管萎缩比肾小球病变更能预测长期肾脏结局。近期单细胞和空间多组学研究进一步揭示,慢性病肾中的肾小管上皮细胞占据独特的、受到严格调控的状态,这些状态在空间组织的纤维化微环境中协调炎症、代谢重编程和细胞外基质重塑。在这篇综述中,我们提出一个慢性肾脏病进展的全肾单位框架。我们重新审视肾小球范式历史上的主导地位,并总结证据表明肾小管间质损伤是肾功能的主要结构决定因素。然后,我们概述血流动力学-缺氧、代谢-毒性和免疫-炎症损伤如何汇聚于肾小管上皮细胞和管周微血管,触发适应不良的上皮程序——包括细胞周期停滞和衰老、代谢重编程和线粒体功能障碍,以及持续的炎症和促纤维化激活。我们将肾小管间质描述为一个动态的上皮-基质-血管-免疫网络,其中自我强化的纤维化微环境出现。最后,我们讨论整合的、以肾单位为中心的视角的治疗和生物标志物意义,认为疾病修饰策略将需要靶向特定的适应不良肾小管程序及其与间质的串扰,并配合已有的针对肾小球的治疗。

9透析 (1篇)

临床研究 (1篇)

Journal of the American Academy of Dermatology IF 12.3 2026-10 PMID: 40543663
Dermatologists are instrumental in diagnosing and treating dermatologic manifestations of end-stage kidney disease (ESKD), and affected patients require a multidisciplinary team-based approach to management. In part 2 of this two-part continuing medical education series, we review dermatologic manifestations associated with the management and therapeutics of ESKD. Herein, we highlight the epidemiology, clinical presentation, and management of unique treatment-associated dermatoses in patients with ESKD, including calciphylaxis, dialysis-related amyloidosis, access steal syndrome, acroangiodermatitis, and nephrogenic systemic fibrosis.
中文摘要:皮肤科医生在诊断和治疗终末期肾病(ESKD)的皮肤表现方面发挥重要作用,受影响患者需要多学科团队协作管理。在这个由两部分组成的继续医学教育系列的第二部分中,我们综述了与ESKD管理和治疗相关的皮肤表现。在此,我们重点介绍ESKD患者中独特的治疗相关皮肤病的流行病学、临床表现和管理,包括钙化防御、透析相关淀粉样变性、通路窃血综合征、肢端血管皮炎和肾源性系统性纤维化。